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Abstract: Many currently licensed and commercially available human vaccines contain 
insoluble aluminum salts as vaccine adjuvants. The primary particles of aluminum 
(oxy)hydroxide and aluminum (hydroxy)phosphate are in the nanometer-scale. However, 
when dispersed in an aqueous solution, the primary particles aggregate to form larger 
microparticles of 1-20 µm. A major limitation with these vaccines is that they must not be 
exposed to freezing temperatures during transport or storage such that the liquid vaccine 
freezes, because slow freezing causes irreversible coagulation that damages the vaccines 
(e.g., loss of efficacy). Therefore, vaccines that contain aluminum salts as adjuvants are 
formulated as liquid suspensions and are required to be kept in a cold chain (2-8o C) during 
transport and storage. Formulating vaccines adjuvanted with aluminum salts into dry 
powder that can be readily reconstituted before injection could address this limitation. 
Spray freeze-drying of vaccines with low concentrations of aluminum salts and high 
concentrations of trehalose alone, or a mixture of sugars and amino acids, as excipients can 
convert vaccines containing aluminum salts into dry powder, but fails to preserve the 
 ix 
particle size and/or immunogenicity of the vaccines. In this dissertation, using ovalbumin 
as a model antigen adsorbed onto aluminum (oxy)hydroxide or aluminum 
(hydroxy)phosphate, a commercially available tetanus toxoid vaccine adjuvanted with 
potassium aluminum sulfate, a human hepatitis B vaccine adjuvanted with aluminum 
(oxy)hydroxide, and a human papillomavirus vaccine adjuvanted with aluminum 
hydroxyphosphate sulfate, it was showed that vaccines containing a relatively high 
concentration of aluminum salts (up to ~1%, w/v, of aluminum hydroxide) can be 
converted into a dry powder by thin-film freeze-drying by using low levels of trehalose 
(i.e., as low as 2% w/v) as an excipient. Importantly, the thin-film freeze-drying process 
did not cause particle aggregation, nor decreased the immunogenicity of the vaccines upon 
reconstitution. Moreover, we showed that the immunogenicity of thin-film freeze-dried 
OVA-adsorbed Alhydrogel® vaccine powder was not significantly changed after it was 
exposed for an extended period of time in temperatures as high as 40o C or subjected to 
repeated slow freezing-and-thawing. Nasal vaccination using a dry powder vaccine 
formulation represents an attractive, non-invasive delivery with better storage stability and 
provides added protection at mucosal surfaces. In this dissertation, we also demonstrate the 
feasibility of nasal immunization using the dry powder formulation of insoluble aluminum 
salt adjuvanted vaccines and a novel intranasal (IN) delivery technology. Special emphasis 
was put on the characterization of the formulation that can be realistically used in humans 
by a nasal dry powder delivery device. The dry powder vaccine elicited a significant serum 
antibody response in rats compared to that of liquid vaccine administered via subcutaneous 
injection or IN route. Significant mucosal specific IgA responses were also observed solely 
 x 
after IN delivery. In addition, in vitro nasal deposition study using nasal casts of adult 
humans using a novel nasal dry powder device shows that out of the total recovered powder 
developed showed that out of the recovered powder (~60%), about 90% stayed in the nose. 
This study demonstrates for the first time to our best knowledge the generation of potent 
systemic and mucosal immune responses using the dry powder form of an aluminum salt-
adjuvanted vaccine and suggests dry powder vaccine formulations are a promising 
approach for mucosal vaccination targeting the nasal mucosa. Thin-film freeze-drying is a 
viable platform technology to produce dry powders of vaccines that contain aluminum 
salts. It is expected that immunization programs can potentially benefit by integrating thin-
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1.1 INTRODUCTION TO VACCINE ADJUVANTS 
Immunization is one of the most powerful and cost-effective of all health 
interventions (1). Immunization averts an estimated 2.5 million deaths a year. For example, 
with the help of immunization, polio has been eradicated in three of World Health 
Organization’s (WHO) six regions and is today endemic in only four countries, down from 
125 countries in 1988. A vaccine formulation generally includes various components. One 
major component of a vaccine formulation is the antigen. An antigen is any molecule that 
can bind specifically to an antibody and has the potential to generate an immune response 
(2). In the conventional vaccines, the antigen usually consists of dead bacteria, dead or live 
attenuated virus, or toxoid. These antigens are highly immunogenic, but they can 
potentially cause human health hazards as well. The newer generation vaccines consist of 
recombinant proteins, peptides, or polysaccharides as an antigen. The newer generation 
vaccines are preferred for safety reasons, but they are only weak immunogenic and usually 
require additional components to help stimulate strong and protective immunity (2). These 
components are termed as vaccine 'adjuvants'. An adjuvant is any substance that can 
enhance the immune responses to an antigen with which it is mixed, but is not 
immunogenic itself (3, 4). A vaccine adjuvant may enhance antigen-specific immune 
responses, prolong immune responses, and/or affect the type of immune responses. In 
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addition, use of a vaccine adjuvant may also reduce the number of immunization required 
in an immunization protocol and help to develop single dose immunization that can reduce 
the overall immunization costs. Ramon (1925) first demonstrated that it is possible to 
increase levels of diphtheria or tetanus antitoxins by the addition of bread crumbs, agar, 
tapioca, starch oil, lecithin, or saponin to diphtheria or tetanus vaccines (5). 
1.2 ALUMINUM SALTS AS VACCINE ADJUVANT 
Mineral salts such as insoluble aluminum salts and calcium phosphate have been 
used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants have been used 
in immunization programs for decades to help induce early, high-titer, and long-lasting 
protective immunity. Aluminum compounds, including aluminum (hydroxy)phosphate 
(AlPO4), aluminum (oxy)hydroxide (Al(OH)3), and alum precipitated vaccines - 
historically referred to as protein aluminate - are currently the most commonly used 
adjuvants in human and veterinary vaccines. According to the WHO, in 2015, the global 
vaccine market is valued more than $41 billion, compared to $24 billion in 2013. Out of 
which, aluminum salt-adjuvanted vaccines take up more than 50% of them (6-8). 
Diphtheria-tetanus-pertussis vaccines, hepatitis A vaccines, hepatitis B vaccines, 
pneumococcal conjugate vaccines, anthrax vaccine, and rabies vaccines, all contain 
aluminum salts as adjuvants (9-12). In fact, 9 out of the top 15 best-selling vaccines contain 
an aluminum salt as an adjuvant (8, 9).  
Aluminum salt-containing adjuvants are often referred to as ‘alum’ in the literature, 
which is deceptive, because (1) alum, chemically potassium aluminum sulfate 
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(KAl(SO4)2·12H2O), has not been widely used as an adjuvant in human vaccines, and (2) 
aluminum hydroxide and aluminum phosphate have different physical characteristics (13) 
and differ in their adjuvant properties (14). Potassium alum was originally used to partially 
purify protein antigens, particularly tetanus and diphtheria toxoids, by precipitating them 
in the presence of anions including phosphate, sulfate, and bicarbonate, resulting in a 
mixture of compounds, mainly aluminum phosphate and aluminum hydroxide (15, 16). 
While aluminum hydroxide and aluminum phosphate adjuvants are chemically referred to 
as Al(OH)3 and AlPO4, they are not stoichiometrically true. Aluminum hydroxide is a 
crystalline aluminum oxyhydroxide, which is positively charged at physiological pH (i.e., 
isoelectric point (pI) = 11) (14, 17, 18). Aluminum phosphate is an amorphous aluminum 
(hydroxy)phosphate, which is negatively charged at physiological pH (pI = 5–7) (14, 17, 
18). One of the earliest uses of an aluminum salt as an adjuvant was reported by A. T. 
Glenny and co-workers in 1926, who showed that the suspension of alum-precipitated 
diphtheria toxoid has a higher immunogenicity than the toxoid alone (19). The use of alum-
precipitated tetanus and diphtheria toxoids has declined considerably because of the 
variability in production of alum-precipitated toxoids (12, 15, 16, 20). However, aluminum 
adjuvanted vaccines have become widely used since then. The immunogenicity of antigens 
adsorbed onto aluminum salt-based adjuvants depends on several factors, but the most 
important include the degree of adsorption of the antigens onto the adjuvants and the dose 
of adjuvants (11, 13, 17, 21).  
The search for alternative and improved vaccine adjuvants continues today, but 
aluminum salt-containing adjuvants are like to remain a mainstay in vaccine formulations 
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due to their excellent record of safety (11-14, 16, 21, 22). Due to the popularity of the 
aluminum compounds as adjuvants in human vaccines, they have become the point of 
reference for evaluating new adjuvants. Although aluminum salts have been used for 
decades, their methods of preparation remain traditional, in which antigens are simply 
adsorbed onto adjuvants. The primary particles of aluminum hydroxide are in the 
nanometer-scale, however, due to their poor water solubility, when dispersed in water, the 
primary particles aggregate to form larger microparticles of 1-20 µm. Therefore, a vaccine 
that is prepared by binding an antigen with an aluminum salt is physically a suspension of 
aluminum salt particles with antigens adsorbed onto them. However, adsorption of antigens 
on aluminum salt-based adjuvants depends on various factors including physical and 
chemical characteristics of the antigens, the type of aluminum salt used, conditions of 
adsorption, charges on adjuvants and antigens, the pH of the formulation, the size of the 
aluminum salt particles, the order of addition of reagents, and the speed of mixing (13, 14, 
21-25). Because it is difficult to manufacture aluminum adjuvants consistently and 
reproducibly, and a poorly formulated aluminum adjuvant preparation does not have the 
optimal adjuvant activity (23, 26), Alhydrogel® (aluminum (oxy)hydroxide) and Adju-
phos® (aluminum (hydroxy)phosphate) from Superfos Biosector (now Brenntag Biosector, 
A/S) have been chosen as a scientific standard in an independent scientific workshop in 
Greece for the evaluation of new adjuvants and to minimize batch-to-batch variability (27, 
28). 
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1.3 MECHANISM OF ACTION FOR ADJUVANT ACTIVITY OF ALUMINUM SALTS 
Many human vaccines contain insoluble aluminum salts as adjuvants (29, 30). 
Although insoluble aluminum salts have been used in vaccines for decades, their exact 
mechanisms of action have baffled scientists for years (31, 32). Over the years, various 
theories have been proposed to explain the mechanisms underlying the adjuvant activity of 
insoluble aluminum salts. It is clear now that aluminum salts work by a mixture of different 
mechanisms. Proposed mechanisms of immunopotentiation by aluminum-containing 
adjuvants include formation of antigen depot (33, 34), stimulation of antigen-presenting 
cells such as dendritic cells (DCs) (35), complement activation (36), and stimulation of 
chemokine release (31, 36). Moreover, there are reports showing that aluminum salts 
activate intracellular pathogen pattern recognition receptor signaling pathway involving 
the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome (37, 
38). Potent inflammatory cytokines such as IL-1β and IL-18 are released in response to 
NLRP3 activation, which direct the host responses to infection and injury (39). 
Furthermore, Kool and colleagues reported that the immunopotentiating effect of 
aluminum salts depends on the induction of uric acid (40).  
Previously we and others discovered that adjuvant activity of aluminum 
(oxy)hydroxide and aluminum (hydroxy)phosphate could be significantly improved by 
reducing the size of the particles in the aqueous suspensions of the insoluble aluminum 
salts from micrometer scale to nanometer scale (e.g. from 1-20 µm to ~100 nm) (41-44). 
We further provided evidence that the more potent adjuvant activity of the aluminum salt 
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nanoparticles is likely related to their stronger ability in activating the NLRP3 
inflammasome than aluminum salt microparticles (42).  
1.4 LIMITATIONS OF ALUMINUM SALT-ADJUVANTED VACCINES 
1.4.1 Freezing of vaccines is critical issue 
The size of aluminum hydroxide and aluminum phosphate particles is in the 
nanometer range. However, these particles when dispersed in aqueous solution aggregate 
to make microparticles of 1-20 µm (54). Thus, a vaccine that is prepared by binding an 
antigen with an aluminum salt is physically a suspension of aluminum salt particles with 
antigens adsorbed on them. In order to maintain highest level of potency, the vaccines must 
be kept in cold-chain (2-8˚C) during storage and transport (55). A major limiting factor 
with these vaccines is that they must not be exposed to freezing conditions during transport 
and storage. Inadvertently exposing the suspension to freezing temperatures causes 
irreversible coagulation of aluminum salts that damages the vaccines (e.g., loss in potency 
and stability) (55).  
Despite the best efforts, temperature excursions during cold-chain is common for 
many reasons such as improperly maintained or outdated refrigerator, loss of power, poor 
compliance with cold-chain procedures, inadequate monitoring and poor understanding of 
the dangers of freezing the vaccines (56). Vaccines that have been accidentally exposed to 
freezing conditions before administration to patients must be discarded, causing significant 
product waste and limited utility. This is significant considering that estimated 75-100% 
of vaccine shipments are exposed to freezing temperatures at some time during shipment 
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(57). This is a budding issue as number of freeze-sensitive vaccines increases. It is 
estimated that freeze-sensitive vaccines represent over 31% of the US $439 million UN 
Children's fund spent on all vaccines (57). 
Meanwhile, as the costs and/or logistical constraints of vaccine delivery associated 
with the cold-chain requirements significantly obstructs global vaccine access, there is 
increasing interest in novel approaches to vaccine stability management such as controlled 
temperature chain (CTC) storage (45, 46). CTC allows vaccines to be managed in 
temperatures outside of the traditional cold-chain for a limited period of time, typically a 
single excursion into ambient temperature not exceeding 40° C for the duration of a specific 
number of days prior to administration (47). For example, in 2012, MenAfriVacTM became 
the first to be prequalified by the World Health Organization (WHO) to receive regulatory 
approval during mass vaccination that allowed vaccine storage at or below 40° C for up to 
4 days (45, 48, 49). It is estimated that by using CTC, the costs of using cold-chain and the 
associated logistics can be reduced by 50% (48).  
1.4.2 Aluminum salts are weakly immuniogenic 
It is well-known that aluminum salts as adjuvants predominantly help induce 
antigen-specific humoral immune responses or T helper type 2 (Th2) biased cellular 
immune responses (50). Aluminum salt-adjuvanted vaccines can only weakly boost 
specific antibody responses, and its inability to help induce cellular immune responses has 
triggered researchers to search for alternative adjuvants (21, 41). Novartis’ MF59 and 
GlaxoSmithKline’s AS03 are both vaccine adjuvants that consist of oil-in-water emulsions, 
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comprising of 4.3% of squalene oil as the dispersed oil phase, which is stabilized by two 
non-ionic surfactants (Tween 80 and Span 85), and a low ionic strength citrate buffers as 
continuous phase (51, 52). AS04 contains 3-O-desacyl-40-monophosphoryl lipid A (MPL) 
derived from the lipopolysaccharide (LPS) of Salmonella minnesota, R595 (53) and 
aluminum hydroxide or aluminum phosphate in a 1 to 10 ratio (w/w) (52). AF03 is a novel 
squalene-in-water emulsion manufactured by a phase inversion temperature emulsification 
process and is recently approved in human influenza vaccine HumenzaTM (54, 55). 
Virosomes are a biodegradable and non-toxic adjuvant system that contains virus 
envelopes devoid of inner core and genetic materials (56). Virosomal adjuvant system 
induces both B- and T-cell responses and is approved in variety of vaccines (57). 
MontanideTM ISA51 is composed of a light mineral oil and a surfactant designed to make 
a water-in-oil emulsion (58).   
1.5 APPROACHES TO OVERCOME THE LIMITATIONS 
There is great interest in addressing this problem, and the strategies to solve it are 
generally two-fold. The first is to add stabilizing reagents in the vaccines to prevent 
aggregation during freezing. For example, the Program for Appropriate Technology 
(PATH) and its research collaborators have shown that adding glycerin, polyethylene 
glycol 300, or propylene glycol into vaccines adjuvanted with aluminum salts prevents 
vaccine aggregation and preserves vaccine efficacy, even after the vaccine is subjected to 
multiple exposures to -20o C (59). Zapata et al. also reported that the adsorption of 
polymers or surface-active agents, such as hydroxypropyl methylcellulose, sodium lauryl 
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sulfate, and polysorbate 80, on aluminum hydroxide prevents aggregation after a freeze-
thaw cycle (60). It is thought that the stabilizing agents produce a large steric repulsive 
region between particles and hinder particle-particle interaction (60). The strength of the 
repulsive region formed by stabilizing agents is proportional to their molecular length (60). 
However, the addition of the aforementioned excipients into vaccine may result in a more 
complex formulation and increase the cost per dose of the vaccine.  
Another strategy is to convert aluminum salt-adjuvanted vaccines into a solid form 
using novel freezing and/or drying techniques. Various methods, such as vacuum-foam 
drying (61), spray drying (62), spray freeze-drying  (63), and spray freezing into liquid 
(64), have been previously explored to convert protein products into dry powders. Spray 
freeze-drying has been extensively studied for freeze-drying vaccines that contain 
aluminum salts (65, 66). Maa et al. suspended an aluminum hydroxide-adjuvanted 
hepatitis-B surface antigen (Alum-HBsAg) vaccine into mannitol, glycine, and dextran, 
with final aluminum hydroxide concentration adjusted to 3% or 0.6% (w/v), sprayed 
atomized liquid droplets (within the range of 20–80 μm) of the Alum-HBsAg vaccine into 
a liquid nitrogen-containing pan, and then placed the pan containing frozen particles in 
liquid nitrogen to a precooled (−55° C) shelf freeze dryer to lyophilize the particles into a 
dry powder (63). After reconstitution, the size of the particles in the Alum-HBsAg vaccine 
did not increase (63). The authors also evaluated the anti-HBsAg IgG titers induced by the 
reconstituted Alum-HBsAg vaccines in mice and compared them with the original 
untreated Alum-HBsAg vaccine. Unfortunately, the reconstituted vaccines were 
administered by intraperitoneal injection and the untreated Alum-HBsAg vaccine was 
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injected intramuscularly (63), making it impossible to conclude whether the spray freeze-
dried vaccines were as immunogenic as the untreated vaccine. Nonetheless, the 
formulations that contained 3% (w/v) of aluminum hydroxide induced an anti-HBsAg IgG 
titer that was close to 10-fold less than that induced by the untreated Alum-HBsAg vaccine, 
and the anti-HBsAg IgG titer induced by the formulation with 0.6% of aluminum 
hydroxide was about 2-fold less than that induced by the untreated Alum-HBsAg vaccine 
(63). It was concluded that lowering alum concentration and fast freezing are the most 
effective formulation parameters in minimizing particle coagulation and thus maximizing 
the immunogenicity of the vaccine (63).  
Clausi et al. used a similar spray freeze-drying method to dry lysozyme or alkaline 
phosphatase adjuvanted with aluminum hydroxide (Alhydrogel) or aluminum phosphate 
(67, 68). The lysozyme vaccine formulations were prepared consisting of 25 mM sodium 
succinate (pH 4.0), 10 µg/ml lysozyme, 0.2 w/v% of either aluminum hydroxide or 
aluminum phosphate, and 0, 2, or 7.5 w/v% trehalose (68). The vaccines were spray-frozen 
by dropping ∼20 µl droplets into liquid nitrogen and then lyophilized. As a control, the 
vaccines were also slowly tray-frozen by placing the samples in lyophilizer, equilibrating 
1 h at a shelf temperature of 0°C, then cooling the shelves at 0.5° C/min to −40° C (“tray-
freezing”) (68). The size of the particles in the reconstituted vaccines after tray freeze-
drying or spray freeze-drying was generally larger than the size of the particles in the 
originally prepared formulation (68). All of the lyophilized formulations were easily 
reconstituted with water, and the adjuvant particles were well dispersed upon gentle 
shaking. However, noticeable settling of the lyophilized vaccines was observed within a 
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few minutes of sitting, especially in formulations without trehalose (vs. about 30 min for 
all untreated liquid vaccines) (68). Interestingly, when subcutaneously administered into 
mice, the vaccines reconstituted from the freeze-dried vaccines all induced a stronger anti-
lysozyme IgG1 response than the untreated liquid vaccine (68). It was concluded that 
higher cooling rates and higher excipient levels minimize adjuvant agglomeration (68).  
The alkaline phosphatase vaccine formulation used in Clausi and coworkers’ study 
was prepared containing 0.081 mg/mL alkaline phosphatase, 0.2% (w/v) of aluminum 
hydroxide, 7.5% (w/v) trehalose, and 25 mM Tris (pH 7.5) (67). The vaccine was then 
spray freeze-dried or tray freeze-dried as mentioned above. The size of the particles in the 
originally prepared liquid vaccine peaked around 1 µm, but the sizes of the particles in the 
vaccine reconstituted from the spray freeze-dried and tray freeze-dried vaccines peaked 
around 4-5 µm and 10-20 µm, respectively (67). All alkaline phosphatase vaccines, liquid 
or reconstituted from freeze-dried powders, induced similar levels of alkaline phosphatase 
specific IgG1 response in mice (67).  
Spray freeze-drying and tray freeze-drying were also applied to a botulism vaccine 
candidate containing botulinum neurotoxin subtype E (BoNT/E), aluminum hydroxide 
(0.2%, w/v), and trehalose (10%, w/v) (69). When tested in mice, the anti-BoNT/E IgG1 
titers in mice injected with reconstituted spray freeze-dried or tray freeze-dried vaccines 
appeared to be lower, and more variable, than that induced by the untreated liquid vaccine, 
especially when measured after a booster immunization, although it was stated that the 
differences were not significant (69).   
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Thin-film freezing (TFF) has been recently studied in the biopharmaceutical field 
for preparing stable submicron protein particles (70). In the TFF process, a liquid (e.g., 
solution) is spread out on a cryogenic substrate to form a thin film in less than one 
second. The resultant frozen film is then dried by lyophilization. For example, Engstrom 
et al. produced dried protein powders with a diameter of 300 nm using TFF, and the enzyme 
activity of the proteins was fully preserved (70). In the present study, the feasibility of 
freeze-drying vaccines that are adjuvanted with aluminum salts using TFF was tested. 
Ovalbumin (OVA) was initially used as a model protein antigen, and it was adjuvanted 
with aluminum hydroxide or aluminum phosphate and lyophilized after thin-film freezing. 
In addition, a commecially availble veterinary tetanus toxoid vaccine (tetanus antitoxin 
concentrated/purified, Colorado Serum Company, Denver, CO),  a human hepatitis B 
vaccine (Engerix-B, GlaxoSmithKline Biologics), and a human papillomavirus 
quadrivalent vaccine (Gardasil, Merck & Co.) were also successfully converted into dry 
powders using the thin-film freeze-drying (TFFD) method. It was concluded that TFFD 
can be used to convert vaccines that are adjuvanted with aluminum salts into dry powder, 
without causing particle aggregation or decreasing the immunogenicity of the vaccines.  
1.6 NEEDLE-FREE IMMUNIZATION 
Immunization is one of the most powerful and cost-effective of all health 
interventions (71). It averts an estimated 2.5 million deaths a year. Over 100 million 
children are immunized every year but despite the success, millions of children in 
developing countries- almost 20% of all the children born every year (around 24 million) 
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- do not get the complete immunizations scheduled for their first year of life (71).Vaccines 
are given mostly by injections. WHO estimates that around 12 billion injections are given 
every day out of which 5% are used for immunizations (72). Fear of needles is critical issue 
for both adults and children (73). Besides that, accidental needle sticks are a serious 
problem in both developed and developing countries. Even greater shortcoming is 
improper and unsafe use of needles (72). According to WHO, one-third of immunization 
injections are unsafe in four of the six geographical regions (71). Another risk of needle-
stick injury is transmission of the blood-borne pathogens (74). Development of needle-free 
immunization has been identified as an important goal in global health care (75).  
The problems associated with vaccine stability urges new vaccine formulations 
with better stability. Approaches for needle-free immunization include cutaneous and 
mucosal immunization. Cutaneous methods of immunization include following: liquid-jet 
injection, which uses high pressure narrow jet of the liquid vaccine stream into intradermal, 
subcutaneous or intramuscular regions (76); epidermal powder immunization which is a 
ballistic method that can efficiently deliver powdered vaccines to the epidermis (77). 
Mucosal immunization methods involve delivery of vaccines to mucosal membranes such 
as ocular, nasal, pulmonary or rectal membrane. Oral delivery of non-living vaccines has 
proved to be extremely challenging due to deactivation of the vaccine in the acidic 
environment of the gastrointestinal tract (78). Vaginal or rectal immunizations suffers 
disadvantages of poor patient compliance. Given that many pathogens invade the host via 
mucosal membrane, nasal and pulmonary routes are attractive site for immunization (79).  
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1.7 POWDER VACCINES FOR INTRANASAL DELIVERY 
Aluminum salt-adjuvanted vaccines are generally administered by subcutaneous, 
intradermal, or intramuscular injection. However, reconstituting the dry powder vaccine 
before injection has various limitations such as the need for sterile water for injection, the 
need for trained medical personnel, and the increased chance of error made when 
reconstituting the powder and filling syringes. The nasal route for immunization offers 
some interesting opportunities. Almost all infectious agents enter the body through the 
mucosal surfaces (80), and the nasal mucosa is often the first point of contact for inhaled 
pathogens. Therefore, ideally, to more effectively protect against inhaled pathogens, 
vaccines should be administered via the nasal mucosal surface to induce mucosal immunity 
to prevent infectious agents from entering the host (81). Besides enabling vaccines to 
induce both mucosal and systemic immune responses (82, 83), intranasal immunization 
has several other advantages as well. For example, the nose tissue is easily accessible and 
highly vascularized, and can be used in the case of epidemics for mass vaccination. In 
addition, nasal immunization enables needle-free, non-invasive delivery of vaccines with 
the possibility of self-immunization.  
Despite the demonstrated efficacy and advancement in the science of nasal delivery 
technology, there are no commercially available nasal dry powder vaccines in the market. 
The major barrier lies in the development of appropriate formulations for these antigen 
candidates. First of all, we need a stable formulation of antigen with adjuvant. Antigens 
are attached with adjuvants with either physical adsorption, or covalently attached. Some 
adjuvants are added with antigen without any attachment. Aluminum salts are attached 
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with antigens using physical adsorption. So, any type of physical strain makes the weak 
bonds susceptible to break. The challenge lies in making a stable dry vaccine powder 
formulation without affecting stability of the antigens or without affecting the tertiary and 
quaternary structure of the antigen.  
 For example, during SD and SFD, the material is subjected to stresses that may be 
harmful to the antigenicity of the vaccine (84). In SD, it is atomization stress, drying stress 
and dehydration stress, where as in SFD, it is atomization stress, freezing stress and 
dehydration stress (85-87). Also, size reduction technology, such as jet mill or pearl mill, 
can generate heat and chances are there that the antigens is detached from the adjuvant. 
Several studies have shown that these stresses can be prevented by adding sugars to the 
liquid feed (88-90). Sugars can form glassy matrix, if properly dried (91). Incorporation of 
proteins in sugar glass can also increase the shelf life. Mechanism of stabilization by sugar 
glasses: (1) the glassy sugar matrix can reduce the mobility of entrapped 
biopharmaceuticals (92). (2) Sugars act as a physical barrier to prevent aggregation 
between two biopharmaceutical molecule (93). (3) Sugar molecules replace water 
molecules that form hydrogen bonds with the biopharmaceuticals (90). A good stabilizer 
should have low number of reducing groups and high glass transition temperature.  
 Previously, it was thought that aluminum salt-based adjuvants are not capable of 
potentiating mucosal immune responses when given intranasally, and results from prior 
studies were ambiguous (94-97). However, data from our recent studies clearly showed 
that intranasal immunization with antigens adsorbed on Alhydrogel® induces significantly 
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stronger antigen-specific immune responses, both systemically and in nasal and lung 
mucosa, as compared to intranasal immunization with the antigens alone (98).  
1.8 OBJECTIVES 
 As mentioned earlier in section 1.4, unintentional freezing during transport and 
storage is a common place and not resource limited. According to WHO, the vaccines that 
have been exposed to freezing temperatures accidentally, have to be discarded. This in 
effect causes costly waste of global vaccine supplies and/or the widespread delivery of 
vaccines with compromised potency. The motivation of this dissertation is to overcome 
this significant unmet need of the insoluble aluminum salt-adjuvanted vaccines in the 
vaccine industry. For the first part, we present here a novel freeze-drying method to prepare 
stable formulations of the aluminum salt-adjuvanted vaccines. Furthermore, there is an 
increasing interest in novel approaches to vaccine stability management such as the 
controlled temperature chain (CTC) storage, which allows vaccines to be managed in 
temperatures outside of the traditional cold-chain for a limited period. To test that, long 
term thermal stability and the freeze stability of the dry powder formulation was evaluated. 
At last, the nasal delivery of these stable dry powder formulations which enables needle-
free, noninvasive delivery of vaccines with a possibility of self-immunization was tested. 
The specific hypothesis of each studies are as follows:   
• To test the feasibility of freeze-drying vaccines that are adjuvanted with 
insoluble aluminum salts using a novel ultra-rapid freezing technique called 
thin-film freeze-drying (TFFD). In this study, six different aluminum salt-
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adjuvanted vaccines and five different aluminum-containing adjuvants are tested to 
evaluate the aggregation of the aluminum salt after converting to dry powder 
vaccine. Out of those, two dry powder vaccine formulations are compared to 
evaluate the antibody responses in a mouse model (Chapter two).  
• To evaluate the thermal and freeze stability of a thin-film freeze-dried (TFFD) 
aluminum salt adjuvanted dry powder vaccine formulations. In this study, the 
immunogenicity of the dry vaccine powder formulation was evaluated in 
temperatures as high as 40 ºC for up to 6 months, as well as after the dry powder 
vaccine formulation was subjected to repeated slow freezing-and-thawing cycles 
(Chapter three).  
• To evaluate the systemic and mucosal antibody responses induced by dry 
powder vaccine of aluminum salt adjuvanted vaccines when administered 
intranasally. In this study, a novel dry powder delivery device was invented. Also, 
the dry powder vaccine formulation of aluminum salt adjuvanted vaccine was 
further characterized to determine its feasibility towards intranasal immunization 









A method of lyophilizing vaccines containing aluminum salts into a dry 
powder without causing particle aggregation or decreasing the 
immunogenicity following reconstitution1 
2.1 INTRODUCTION 
Some aluminum salts, including aluminum hydroxide and aluminum phosphate, 
have been widely used as human vaccine adjuvants for decades. The primary particles of 
aluminum hydroxide and aluminum phosphate are in the nanometer-scale. However, when 
dispersed in an aqueous solution, the primary particles aggregate to form larger 
microparticles of 1-20 µm (99, 100). Thus, a vaccine that is prepared by binding an antigen 
with an aluminum salt is physically a suspension of aluminum salt particles with antigens 
adsorbed on them. Three mechanisms are frequently cited to explain the mechanisms 
underlying the adjuvant activity of aluminum salts (35, 36, 100-102): i) for decades, it was 
thought to be the depot effect. Aluminum salts form an antigen depot at the injection site, 
from where the antigens are slowly released (103); ii) Aluminum salts induce 
inflammation, thus recruiting and activating antigen-presenting cells that capture antigens 
(104); iii) The adsorption of soluble antigens on aluminum salt particles makes them 
                                                 
1This Chapter is based on “Sachin G. Thakkar*, Xinran Li*, Tinashe B Ruwona, Robert Williams 
III, Zhengrong Cui, Journal of Controlled Release, April 2015, 204: 38–50. *authors contributed equally. 
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readily taken up by antigen-presenting cells (104). Finally, recent data showed that the 
molecular target for the pro-inflammatory activity of aluminum salts is the NOD-like 
receptor protein 3 (NLRP3) (104-108).   
Many currently licensed and commercially available vaccines, including 
diphtheria-tetanus-pertussis vaccines, Hepatitis A vaccines, Hepatitis B vaccines, 
Pneumococcal conjugate vaccines, anthrax vaccine, human papillomavirus vaccine, and 
Rabies vaccines, contain aluminum salts as adjuvants (109). However, a major limiting 
factor with these vaccines is that they must not be exposed to freezing conditions during 
transport and storage, and are too fragile to be stable at ambient temperatures. In other 
words, vaccines that are adjuvanted with aluminum salts must remain stored as a liquid 
suspension at 2-8o C from manufacturing to being administered to patients, because 
inadvertently exposing the suspension to freezing temperatures causes irreversible 
coagulation that damages the vaccines (e.g., loss in activity and stability) (59). Vaccines 
that have been incidentally exposed to freezing conditions before administration to patients 
must be discarded, causing significant product waste and limited utility. This is significant 
considering that an estimated 75-100% of the vaccine shipments are actually exposed to 
freezing temperatures at some points during shipment (110), resulting in costly waste and 
the loss of nearly half of all global vaccine supplies (46).  
There is great interest in addressing this problem, and the strategies to solve it are 
generally two-fold. The first is to add stabilizing reagents in the vaccines to prevent 
aggregation during freezing. For example, the Program for Appropriate Technology 
(PATH) and its research collaborators have shown that adding glycerin, polyethylene 
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glycol 300, or propylene glycol into vaccines adjuvanted with aluminum salts prevents 
vaccine aggregation and preserves vaccine efficacy, even after the vaccine is subjected to 
multiple exposures to -20o C (59). Zapata et al. also reported that the adsorption of 
polymers or surface-active agents, such as hydroxypropyl methylcellulose, sodium lauryl 
sulfate, and polysorbate 80, on aluminum hydroxide prevents aggregation after a freeze-
thaw cycle (60). It is thought that the stabilizing agents produce a large steric repulsive 
region between particles and hinder particle-particle interaction (60). The strength of the 
repulsive region formed by stabilizing agents is proportional to their molecular length (60). 
However, the addition of the aforementioned excipients into vaccine may result in a more 
complex formulation and increase the cost per dose of the vaccine.  
Another strategy is to convert aluminum salt-adjuvanted vaccines into a solid form 
using novel freezing and/or drying techniques. Various methods, such as vacuum-foam 
drying (61), spray drying (62), spray freeze-drying  (63), and spray freezing into liquid 
(64), have been previously explored to convert protein products into dry powders. Spray 
freeze-drying has been extensively studied for freeze-drying vaccines that contain 
aluminum salts (65, 66). Maa et al. suspended an aluminum hydroxide-adjuvanted 
hepatitis-B surface antigen (Alum-HBsAg) vaccine into mannitol, glycine, and dextran, 
with final aluminum hydroxide concentration adjusted to 3% or 0.6% (w/v), sprayed 
atomized liquid droplets (within the range of 20–80 μm) of the Alum-HBsAg vaccine into 
a liquid nitrogen-containing pan, and then placed the pan containing frozen particles in 
liquid nitrogen to a precooled (−55° C) shelf freeze dryer to lyophilize the particles into a 
dry powder (63). After reconstitution, the size of the particles in the Alum-HBsAg vaccine 
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did not increase (63). The authors also evaluated the anti-HBsAg IgG titers induced by the 
reconstituted Alum-HBsAg vaccines in mice and compared them with the original 
untreated Alum-HBsAg vaccine. Unfortunately, the reconstituted vaccines were 
administered by intraperitoneal injection and the untreated Alum-HBsAg vaccine was 
injected intramuscularly (63), making it impossible to conclude whether the spray freeze-
dried vaccines were as immunogenic as the untreated vaccine. Nonetheless, the 
formulations that contained 3% (w/v) of aluminum hydroxide induced an anti-HBsAg IgG 
titer that was close to 10-fold less than that induced by the untreated Alum-HBsAg vaccine, 
and the anti-HBsAg IgG titer induced by the formulation with 0.6% of aluminum 
hydroxide was about 2-fold less than that induced by the untreated Alum-HBsAg vaccine 
(63). It was concluded that lowering alum concentration and fast freezing are the most 
effective formulation parameters in minimizing particle coagulation and thus maximizing 
the immunogenicity of the vaccine (63).  
Clausi et al. used a similar spray freeze-drying method to dry lysozyme or alkaline 
phosphatase adjuvanted with aluminum hydroxide (Alhydrogel) or aluminum phosphate 
(67, 68). The lysozyme vaccine formulations were prepared consisting of 25 mM sodium 
succinate (pH 4.0), 10 µg/ml lysozyme, 0.2 w/v% of either aluminum hydroxide or 
aluminum phosphate, and 0, 2, or 7.5 w/v% trehalose (68). The vaccines were spray-frozen 
by dropping ∼20 µl droplets into liquid nitrogen and then lyophilized. As a control, the 
vaccines were also slowly tray-frozen by placing the samples in lyophilizer, equilibrating 
1 h at a shelf temperature of 0°C, then cooling the shelves at 0.5° C/min to −40° C (“tray-
freezing”) (68). The size of the particles in the reconstituted vaccines after tray freeze-
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drying or spray freeze-drying was generally larger than the size of the particles in the 
originally prepared formulation (68). All of the lyophilized formulations were easily 
reconstituted with water, and the adjuvant particles were well dispersed upon gentle 
shaking. However, noticeable settling of the lyophilized vaccines was observed within a 
few minutes of sitting, especially in formulations without trehalose (vs. about 30 min for 
all untreated liquid vaccines) (68). Interestingly, when subcutaneously administered into 
mice, the vaccines reconstituted from the freeze-dried vaccines all induced a stronger anti-
lysozyme IgG1 response than the untreated liquid vaccine (68). It was concluded that 
higher cooling rates and higher excipient levels minimize adjuvant agglomeration (68).  
The alkaline phosphatase vaccine formulation used in Clausi and coworkers’ study 
was prepared containing 0.081 mg/mL alkaline phosphatase, 0.2% (w/v) of aluminum 
hydroxide, 7.5% (w/v) trehalose, and 25 mM Tris (pH 7.5) (67). The vaccine was then 
spray freeze-dried or tray freeze-dried as mentioned above. The size of the particles in the 
originally prepared liquid vaccine peaked around 1 µm, but the sizes of the particles in the 
vaccine reconstituted from the spray freeze-dried and tray freeze-dried vaccines peaked 
around 4-5 µm and 10-20 µm, respectively (67). All alkaline phosphatase vaccines, liquid 
or reconstituted from freeze-dried powders, induced similar levels of alkaline phosphatase 
specific IgG1 response in mice (67).  
Spray freeze-drying and tray freeze-drying were also applied to a botulism vaccine 
candidate containing botulinum neurotoxin subtype E (BoNT/E), aluminum hydroxide 
(0.2%, w/v), and trehalose (10%, w/v) (69). When tested in mice, the anti-BoNT/E IgG1 
titers in mice injected with reconstituted spray freeze-dried or tray freeze-dried vaccines 
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appeared to be lower, and more variable, than that induced by the untreated liquid vaccine, 
especially when measured after a booster immunization, although it was stated that the 
differences were not significant (69).   
Thin-film freezing (TFF) has been recently studied in the biopharmaceutical field 
for preparing stable submicron protein particles (70). In the TFF process, a liquid (e.g., 
solution) is spread out on a cryogenic substrate to form a thin film in less than one 
second. The resultant frozen film is then dried by lyophilization. For example, Engstrom 
et al. produced dried protein powders with a diameter of 300 nm using TFF, and the enzyme 
activity of the proteins was fully preserved (70). In the present study, the feasibility of 
freeze-drying vaccines that are adjuvanted with aluminum salts using TFF was tested. 
Ovalbumin (OVA) was initially used as a model protein antigen, and it was adjuvanted 
with aluminum hydroxide or aluminum phosphate and lyophilized after thin-film freezing. 
In addition, a commecially availble veterinary tetanus toxoid vaccine (tetanus antitoxin 
concentrated/purified, Colorado Serum Company, Denver, CO),  a human hepatitis B 
vaccine (Engerix-B, GlaxoSmithKline Biologics), and a human papillomavirus 
quadrivalent vaccine (Gardasil, Merck & Co.) were also successfully converted into dry 
powders using the thin-film freeze-drying (TFFD) method. It was concluded that TFFD 
can be used to convert vaccines that are adjuvanted with aluminum salts into dry powder, 





2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Dried aluminum hydroxide gel (AH gel) and aluminum phosphate were from 
Spectrum Chemical and Laboratory Products (Gardena, CA). OVA, trehalose, and 
Laemmli sample buffer were from Sigma-Aldrich (St. Louis, MO). Bio-safeTM Coomassie 
blue staining solution and Bio-Rad DCTM protein assay reagents were from Bio-Rad 
Laboratories (Hercules, CA). Alhydrogel® (2%, w/v) was from InvivoGen (San Diego, 
CA). Tetanus antitoxin concentrated/purified (TT vaccine) was from Colorado Serum 
Company (Denver, CO). The TT vaccine contains potassium alum (personal 
communication with Dr. Randall Berrier at Colorado Serum). Potassium alum is also 
known as potassium aluminum sulfate. Engerix-B, a human hepatitis B vaccine from 
GlaxoSmithKline, and Gardasil, a human papillomavirus quadrivalent vaccine from Merck 
& Co., Inc., were purchased through the University of Texas at Austin University Health 
Services. Engerix-B contains aluminum hydroxide (0.5 mg of aluminum per ml). Gardasil 
contains amorphous aluminum hydroxyphosphate sulfate (0.45 mg/ml) as an adjuvant. 
Mouse Anti-Tetanus Toxoid Ig’s ELISA kit was from Alpha Diagnostic International (San 
Antonio, TX). Tetanus toxoid was from List Biologics Laboratory (Campbell, CA). 
Purified polyclonal horse anti-tetanus serum and guinea pig anti-tetanus IgG were from the 
National Institute for Biological Standards and Control (Hertfordshire, England).  
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2.2.2 Thin-film freeze-drying (TFFD) 
Three types of aluminum-containing compounds, dried aluminum hydroxide gel 
(USP grade) (AH gel), 2% Alhydrogel®, and aluminum phosphate, were used to adsorb 
OVA as a model antigen. The OVA-adsorbed aluminum hydroxide vaccine was prepared 
by mixing an OVA solution with an aluminum hydroxide suspension in phosphate buffered 
saline (PBS, pH 7.4, 10 mM) to reach an OVA to Al3+ weight ratio of 1:10. The vaccine 
contained 31.4 µg/ml of OVA, 0.09% of aluminum hydroxide, and 0-5% (w/v) of trehalose. 
The OVA-aluminum phosphate vaccine (31.4 µg/ml of OVA, 0.142% (w/v) of aluminum 
phosphate, and 2% (w/v) of trehalose) was prepared similarly. When the 2% Alhydrogel® 
was used, Alhydrogel® (25 ml) was added into a 50 mL tube, followed by the addition of 
25 ml of an OVA solution (1 mg/ml) at an OVA to Al3+ weight ratio of 1:10, and 1 g of 
trehalose to obtain a final formulation with 2% (w/v) of trehalose, ~1% (w/v) of 
Alhydrogel®, and 0.5 mg/mL of OVA. The samples were subjected to TFF and lyophilized 
as described previously (70, 111). Briefly, the aluminum-containing vaccine suspensions 
were dropped onto a pre-cooled rotating cryogenic steel surface to form thin films. The 
thin films were removed by a steel blade. In order to avoid the overlap of two droplets, the 
speed at which the vaccine suspension was dropped on the cryogenic substance was 
controlled at 5-7 rpm. The frozen film-like solids were collected in liquid nitrogen and 
dried using a VirTis Advantage bench top tray lyophilizer (The VirTis Company, Inc. 
Gardiner, NY). Lyophilization was performed over 72 h at pressures less than 200 mTorr, 
while the shelf temperature was gradually ramped from −40°C to 26° C. After 
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lyophilization, the solid vaccine powder was quickly transferred to a sealed container and 
stored in a desiccator at room temperature before further use (112).  
To dry TT vaccine, trehalose was added into the TT vaccine that was diluted 50-
fold in PBS (pH 6.3, 10 mM) to adjust the final concentration of trehalose to 2% (w/v). 
The vaccine was then subjected to TFFD as mentioned above. To dry Engerix-B, trehalose 
was added directly into the commercial vaccine (without pre-dilution) to obtain a 
formulation with 2% (w/v) of trehalose, ~20 µg/mL of HBsAg, and ~500 µg/mL of 
aluminum, and the vaccine was then subjected to TFFD. In Engerix-B vaccine, each 1-mL 
adult dose contains 20 µg of HBsAg adsorbed on 0.5 mg of aluminum as aluminum 
hydroxide. To dry the Gardasil vaccine, 100 μL of the vaccine was diluted to 1 mL of 0.9% 
(w/v) sodium chloride, and trehalose was added to reach a final concentration of 2% (w/v). 
The vaccine was then subjected to TFFD. Each 0.5-mL dose of the original Gardasil 
contains approximately 20 µg of HPV 6 L1 protein, 40 µg of HPV 11 L1 protein, 40 µg of 
HPV 16 L1 protein, and 20 µg of HPV 18 L1 protein. Each 0.5-ml dose of Gardasil also 
contains approximately 225 µg of aluminum (as amorphous aluminum hydroxyphosphate 
sulfate). 
The morphology of the vaccines in suspension was examined under an Olympus 
BX60 microscope (Olympus America, Inc., Center Valley, PA). The size of particles and 
particle size distribution in all samples were determined using a Sympatec Helos laser 
diffraction instrument (Sympatec GmbH, Germany) equipped with a R3 lens. The moisture 
in the dried powder was measured using a Karl Fisher Titrator Aquapal III from CSC 
Scientific Company (Fairfax, VA). 
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2.2.3 Shelf freeze-drying 
An OVA-adsorbed aluminum hydroxide (AH gel) vaccine that contained 2% of 
trehalose (w/v), 0.09% of aluminum hydroxide, and 31.4 µg/mL of OVA in PBS (pH 7.4, 
10 mM) was frozen on the shelf of a -20oC or -80oC freezer overnight and then lyophilized 
using a VirTis Advantage bench top tray lyophilizer as mentioned above. The dry powder 
was stored in a desiccator at room temperature before use. 
2.2.4 The effect of the concentration of trehalose in vaccine on thin-film 
freeze-drying  
To evaluate the effect of the concentration of trehalose on TFFD of vaccines, 
various amounts of trehalose were added into OVA-adsorbed aluminum hydroxide (AH 
gel) in suspension (1:10, OVA vs. Al3+, w/w) to prepare formulations with 0%, 1%, 2%, 
3%, 4%, and 5% of trehalose (w/v). The suspensions were then subjected to TFFD as 
mentioned above.  
2.2.5 The binding efficiency of OVA to the aluminum hydroxide before and 
after TFFD  
SDS-PAGE was used to determine the binding efficiency of OVA to aluminum 
hydroxide before and after TFFD (41). The OVA-adsorbed aluminum hydroxide (AH gel) 
dry powder (OVA to Al3+ ratio, 1 to 10, w/w) was reconstituted and applied on SDS-PAGE 
gel. As a control, OVA alone and freshly prepared OVA-adsorbed aluminum hydroxide 
suspension (with 2% trehalose, w/v) were also included. Samples were mixed with a 
Laemmli sample buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, and 0.01% 
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Bromophenol Blue) before applied to 7.5% Mini-PROTEAN® TGX™ precast 
polyacrylamide gels (Bio-Rad). Precision plus protein standards were also run along with 
the samples at 130 V for 1 h. The gel was then stained in a Bio-SafeTM Coomassie blue 
staining solution and scanned using a Kodak Image Station 440CF (Rochester, NY). The 
intensity of the protein bands in the gel was quantified using the NIH ImageJ software, and 
the binding efficiency was calculated by subtracting the percentage of unbound protein 
(i.e., band intensity from vaccine dry powder or freshly prepared vaccine suspension) from 
the total protein (i.e., band intensity of OVA alone).  
The binding efficiency of the OVA to aluminum hydroxide (AH gel) was also 
determined by centrifuging the OVA-adsorbed aluminum hydroxide, before and after 
TFFD and reconstitution, at about 4500 x rcf for 5 min, and measuring the concentration 
of the OVA in the supernatant using the BCA Protein Assay Reagent from Thermo 
Scientific (Pittsburgh, PA) (113). The amount of OVA bound on the aluminum hydroxide 
was calculated by subtracting the amount of OVA in the supernatant from the total amount 
of OVA added into the vaccine.  
2.2.6 Differential scanning calorimetry (DSC) 
Thermal analyses of the OVA-adsorbed aluminum hydroxide (AH gel) dry powder 
and its individual components, OVA, aluminum hydroxide (AH gel), and trehalose, were 
conducted using a modulated temperature DSC (Model 2920, TA Instruments, New Castle, 
DE) (111). Four to seven milligrams of each sample was weighed into the aluminum pans 
(PerkinElmer Instruments, Norwalk, CT), which were crimped subsequently. An empty 
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aluminum pan was used as a reference. Samples were then heated at a ramp rate of 3oC/min 
from -30°C to 300°C. Data were analyzed using the TA Universal Analysis 2000 software 
(TA Instruments). 
2.2.7 Scanning electron microscopy (SEM) 
The morphology of the OVA-adsorbed aluminum hydroxide (AH gel) dry powder 
and freshly prepared OVA-adsorbed aluminum hydroxide (AH gel) suspension was 
examined using a Zeiss Supra 40 VP scanning electron microscope in the Institute for Cell 
and Molecular Biology Microscopy and Imaging Facility at The University of Texas at 
Austin (114). When preparing the TFFD samples for SEM, one thin layer of the dried 
powder was deposited on the specimen stub using a double stick carbon tape. For the 
freshly prepared OVA-adsorbed aluminum hydroxide suspension, the suspension was 
placed on the specimen stub and allowed to dry overnight. The specimen stubs with 
samples were then placed in the sputter coater chamber and coated with a very thin film of 
lead (Pb) before examination. 
2.2.8 Intrinsic tryptophan fluorescence spectrometry 
The TT vaccine was dried using TFFD and reconstituted before examination. 
Freshly diluted TT vaccine (in a phosphate buffer) was used as a negative control. The 
final trehalose concentration in both samples was 2% (w/v). Fluorescence emission 
spectrum was recorded using a PTI Quanmaster spectrofluorimeter (Photon Technology 
International, Santa Clara, CA). An excitation wavelength of 290 nm was employed, and 
the emission spectrum was collected from 280 nm to 530 nm (115).  
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2.2.9 Repeated freeze-thawing of thin-film freeze-dried vaccine powder 
The dried powders of TT vaccine, Engerix B, and OVA-adsorbed Alhydrogel® 
were subjected to three cycles of freezing (-20oC for 8 h) and thawing (4oC for 16 h), 
reconstituted, and analyzed for particle size distribution. As control, fresh vaccines were 
also subjected to the same three cycles of freezing-and-thawing and examined similarly.  
2.2.10 Animal studies 
All animal studies were carried out following the National Research Council guide 
for the care and use of laboratory animals. The animal protocol was approved by the 
Institutional Animal Care and Use Committee at The University of Texas at Austin. Female 
BALB/c mice, 6-8 weeks of age, were from Charles River Laboratories, Inc. (Wilmington, 
MA). Mice (n = 5) were subcutaneously (s.c.) injected with OVA-adsorbed aluminum 
hydroxide (AH gel) or the TT vaccine, freshly prepared or reconstituted from TFFD 
powder. For the OVA-adsorbed aluminum hydroxide (AH gel), mice were immunized on 
days 0, 14 and 28 with 5 µg, 10 µg, or 20 µg of OVA per mouse. As controls, mice were 
injected with sterile PBS or OVA alone (10 µg) dissolved in PBS. For the TT vaccine, mice 
were immunized on days 0, 14, and 28, and the dose of TT was 3.75 Lf (flocculation units) 
of tetanus toxoid per mouse per injection. Sterile PBS and TT vaccine freshly diluted with 
2% trehalose were used as controls. Sixteen days after the third dose, mice were bled for 
antibody assay. Total anti-OVA IgG levels in serum samples were measured using enzyme-
linked immunosorbent assay (ELISA) as described previously (116). Anti-TT IgG levels 
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were determined using a mouse Anti-Tetanus Toxoid Ig’s ELISA Kit following the 
manufacturer’s instructions. 
2.2.11 Tetanus toxin binding inhibition test (ToBI-test) 
The ToBI-test is an in vitro assay validated to determine the activity of anti-tetanus 
toxoid antiserum in vaccination studies and was adapted (117-119). Briefly, flat bottom 
microplates (Corning Costar, NY, NY) (PI) were blocked for 90 min at 37°C in a 
humidified chamber with 250 µl/well PBS containing 3% bovine serum albumin (BSA, 
Sigma-Aldrich) and 0.05% Tween 20 (PBS-BSA). After washing with PBS containing 
0.05% Tween 20 (PBS-T), mouse serum samples diluted 2-fold serially in Peptone diluent 
(i.e., 1 % peptone, 0.5% NaCl, 0.5% BSA and 0.05% Tween 20) were added into the wells 
(duplicate in 100 µl, starting at 1:200 dilution). Wells, in which serum samples were not 
added, were used as the 100% binding signal in calculating the percent binding. 
Subsequently, 100 µl tetanus toxoid (0.65 µg/ml diluted in 1% peptone and 0.5% Tween 
20) was added into all wells. Wells without tetanus toxoid were also included as a control. 
These microplates were then incubated overnight. A parallel series of plates (Maxisorp® 
Nunc,Thermo Scientific) (P2) were coated with 2 IU/ml of purified polyclonal horse anti-
tetanus serum (NIBSC 60/013, diluted in PBS, 10 mM, pH 7.4) and incubated overnight. 
The next day, these plates were blocked for 90 min with 200 µl per well of PBS-BSA. 
After washing with PBS-T, 100 µl of serum-toxoid mixtures in the P1 microplates were 
transferred to the wells in the P2 microplates and incubated for 90 min. After a third 
washing step, 100 µl guinea pig anti-tetanus IgG (NIBSC 10/132) was added to the wells 
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(1:200 dilution in PBS-BSA) and incubated for 90 min. After washing with PBS-T, 100 µl 
of peroxidase-conjugated goat anti-guinea pig IgG (Sigma-Aldrich) at 1:2000 dilution was 
added and incubated for 60 min. One hundred microliters of 3,3′,5,5′-Tetramethylbenzidine 
(TMB) Liquid Substrate System for ELISA (Sigma-Aldrich) was added and incubated in 
the dark for 15 min. The reaction was stopped by the addition of 100 µl of 2N H2SO4, and 
the absorbance was measured at 450 nm. The percentage of binding (of tetanus toxoid to 
the polyclonal horse anti-tetanus antiserum coated in P2 microplates) was reported as the 
OD450 values of the samples as a percentage of the OD450 values in wells with zero 
percent of inhibition (i.e., tetanus toxoid that was not mixed with any mouse antiserum 
samples).  
2.2.12 Statistics 
Statistical analyses were conducted using analysis of variance followed by 
Fischer’s protected least significant difference procedure. A p-value of < 0.05 (two-tail) 









2.3  RESULT AND DISCUSSION 
2.3.1  Thin-film freeze-drying of OVA-adsorbed aluminum hydroxide  
In order to test whether the TFFD can be used to lyophilize an aluminum hydroxide-
adjuvanted, protein-based vaccine, OVA-adsorbed aluminum hydroxide was suspended in 
2% (w/v) of trehalose and subjected to TFFD. A white powder was formed, which can be 
readily reconstituted with water, PBS, or normal saline with no or only minimal agitation. 
The moisture content in the powder was 1-3%. The size of the particles in the reconstituted 
OVA-adsorbed aluminum hydroxide was 9.7 ± 2.5 µm, which is not different from the size 
of the particles in freshly prepared OVA-adsorbed aluminum hydroxide suspension (9.4 ± 
1.7 µm) (Fig. 1A), demonstrating that the OVA-adsorbed aluminum hydroxide suspension 
can be successfully lyophilized into a dry powder form using TFFD without significantly 
affecting on the size of the particles in the vaccine. The microscopic images in Figs. 1B-C 
also show that subjecting the OVA-adsorbed aluminum hydroxide to TFFD and 
reconstitution did not cause significant aggregation. In contrast, when the same OVA-
adsorbed aluminum hydroxide suspension was frozen by placing it on a -80oC or -20oC 
shelf before lyophilization, significant aggregations were detected (Figs. 1D-E). Zapata et 
al. reported that  aluminum hydroxide gel could form aggregates ranged from 65 to 160 
µm after just one freeze-thaw cycle at -24o C (60). It is thought that the particle 
coagulation/aggregation is due to the large water crystals formed during the slow freezing 
process, which bring aluminum hydroxide particles close enough to overcome repulsive 
forces and cause aggregation, and the original aluminum hydroxide suspension could not 
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be reproduced upon coagulation (63). By increasing the freezing rate, only smaller ice 
crystals are formed as a result of a greater rate of nucleation, which are not strong enough 
to overcome the repulsive forces between particles, and particle aggregation is prevented 
consequently (63). In the TFF process, a solution or suspension is spread out on a cryogenic 
substrate to form a thin film in less than one second (cooling rate, ~100 K/s) (70), which 
may explain why there was not significant aggregation after the OVA-adsorbed aluminum 
hydroxide was subjected to TFFD (and reconstitution). As mentioned early, it was reported 
previously that higher cooling/freezing rates help minimize aggregation/agglomeration of 






























Figure 2.1 TFFD of OVA-adsorbed aluminum hydroxide (OVA-AH gel)  
(A) Particle size distribution before and after the vaccine was subjected to TFFD and 
reconstitution. (B-C) Representative microscopy images of OVA-AH gel before (B) and 
after lyophilization and reconstitution (C-E) with 2% trehalose (w/v). In C-E, the method 
of freezing was TFF, shelf-freezing at -20oC, and shelf-freezing at -80oC, respectively.  
 
B. OVA/AH gel, fresh C. OVA/AH gel, TFFD 
D. OVA/AH gel, -20oC then drying E. OVA/AH gel, -80oC then drying 
A 
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2.3.2  Thin-film freeze-drying of OVA-adsorbed aluminum hydroxide in 
various concentrations of trehalose 
Certain sugars, such as trehalose, mannitol, dextran, and sucrose, have been shown 
to be effective at maintaining protein activity and stabilize aluminum salts in vaccine 
formulations during freezing process (66, 120, 121). Trehalose forms fragile glass during 
freezing, resulting in an increase on the viscosity, which limits the mobility of protein 
molecules or aluminum salt particles, and thus prevents coagulation (120, 122). The 
formation of glass also resulted in a trehalose-containing phase with maximum 
concentration that prevents the non-ice concentration or pH-induced aggregation of 
aluminum salts during freezing (120). The effect of the concentration of trehalose on spray 
freeze-drying vaccines that contain aluminum hydroxide or aluminum phosphate was 
previously studied, and it was concluded that 5-20% (w/v) of trehalose was required to 
successfully spray freeze-dry vaccines adjuvanted with aluminum salts (69). To determine 
the minimal concentration of trehalose needed to prevent aggregation during TFFD, OVA-
adsorbed aluminum hydroxide (AH gel) suspended in various concentrations of trehalose 
(i.e., 0%, 1%, 2%, 3%, 4%, 5%, w/v) was subjected to TFFD. As shown in Fig. 2A, when 
the OVA-adsorbed aluminum hydroxide suspension was subjected to TFFD in the absence 
of trehalose, the mean size of particles after reconstitution was significantly larger than that 
in the freshly prepared OVA-adsorbed aluminum hydroxide suspension, indicating that a 
cryoprotectant such as trehalose is needed to successfully convert the OVA-adsorbed 
aluminum hydroxide into a powder by TFFD. Trehalose at 1% (w/v) was not sufficient 
(Fig. 2A), but 2% of trehalose was enough to help successfully convert the OVA-adsorbed 
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aluminum hydroxide into a dry powder following TFFD, without causing particle 
aggregation (Fig. 2A). Shown in Fig. 2B are the particle size distribution curves of the 
OVA-adsorbed aluminum hydroxide containing various percentages of trehalose after 
subjected to TFFD and reconstitution, and the representative images of OVA-adsorbed 
aluminum hydroxide that were subjected to TFFD with 1%, 2%, and 3% (w/v) of trehalose, 
respectively, are shown in Fig. 2C. In the present study, trehalose alone was used during 
the TFFD process. It is expected that other cryoprotectants such as sucrose, glycine and 
other amino acids, and polymers such as polyvinylpyrrolidone will also help prevent 
aggregation during the TFFD process. For example, in a previous study, Alum-HBsAg 
vaccine was suspended in mannitol, glycine, and dextran before spray freeze-drying (63). 
The concentration of trehalose needed to successfully thin-film freeze-dry OVA-adsorbed 
aluminum hydroxide was only 2% (w/v) (Figs. 2A-B). Trehalose at concentrations of 
above 7.5% or above is generally used when spray freeze-dry vaccines adjuvanted with 
aluminum salts (67-69). Clausi et al. actually spray freeze-dried and tray freeze-dried 
lysozyme adjuvanted with aluminum hydroxide or aluminum phosphate in 2% (w/v) of 
trehalose (68). The particle size of the lysozyme vaccines increased slightly following 
freeze-drying and reconstitution, as compared to the untreated lysozyme vaccines (68). 















Figure 2.2 TFFD of OVA-adsorbed aluminum hydroxide in various concentrations 
of trehalose 
(A-B). Particle sizes (A) and particle size distribution (B) of OVA-AH gel reconstituted 
from powders that were thin-film freeze-dried using various concentrations of trehalose 
(i.e., 0-5%, w/v). (C). Representative images of the dried OVA-AH gel powders prepared 





































vaccines prepared, only 10% of the lysozymes were bound to aluminum salts, and freeze-
drying helped increase the percent of lysozymes that adsorbed to aluminum salts (68). 
2.3.3  Characterization of the thin-film freeze-dried powder of OVA-adsorbed 
aluminum hydroxide 
To understand the influence of the TFFD process on aluminum hydroxide-
adjuvanted vaccines, several studies were conducted to characterize the dried powder of 
the OVA-adsorbed aluminum hydroxide. The desorption of OVA from the aluminum 
hydroxide (AH gel) after the OVA-adsorbed aluminum hydroxide was subjected to TFFD 
was evaluated using SDS-PAGE. It is assumed that the intensity of the OVA band on the 
SDS-PAGE gel image is inversely correlated to the level of free, unbounded OVA in the 
OVA-adsorbed aluminum hydroxide preparation (Fig. 3A). At the OVA to Al3+ weight 
ratio of 1:10, almost all OVA (~98.1%) were bound on the aluminum hydroxide (Fig. 3A, 
NON TFF). After the OVA-adsorbed aluminum hydroxide was subjected to TFFD and 
reconstitution, the percent of OVA that remained adsorbed on the aluminum hydroxide was 
estimated to be 91.3% (Fig. 1A, TFF), suggesting that about 7.2% of (loosely) bound OVA 
protein was desorbed from aluminum hydroxide after the OVA-adsorbed aluminum 
hydroxide was subjected to TFFD and reconstitution. The binding efficiency of the OVA 
to aluminum hydroxide before and after it was subjected to TFFD and reconstitution, as 
determined by measuring the amount of the OVA remained in the supernatant after the 
vaccine was subjected to centrifugation, was 50.8 ± 13.5% and 62.5 ± 8.6%, respectively 
(p = 0.36), which are lower than that determined using the SDS-PAGE electrophoresis 
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mentioned above. When the centrifugation method was used, it is assumed that all OVA 
proteins adsorbed on aluminum hydroxide particles were precipitated after the 
centrifugation. When SDS-PAGE electrophoresis method was used, it is assumed that all 
OVA proteins that adsorbed on the aluminum hydroxide particles did not migrate out of 
the loading wells of the SDS-PAGE gel. The different assumptions may be in part 
responsible for the different binding efficiency values obtained using those two methods. 
Nonetheless, it appears that subjected the OVA-adsorbed aluminum hydroxide to TFFD 
and reconstitution only caused minimum desorption of the OVA from the aluminum 
hydroxide. Finally, it is noted that in this study, sterile PBS (10 mM, pH 7.4) was used to 
dissolve OVA and to prepare aluminum hydroxide (AH gel) suspension to minimize OVA 
denaturing. It was previously reported that pretreatment of aluminum hydroxide with 
selected concentrations of phosphate ions reduces the positive surface charge, which exists 
on the aluminum hydroxide at pH 7.4 (113) . The isoelectric point of OVA was reported to 
be around pH 4.55-4.88 (123). Therefore, if PBS is replaced with other buffers that do not 
contain phosphate ions, the binding efficiency of the OVA to the aluminum hydroxide 
particles may increase and the ratio of the OVA to aluminum may need to be adjusted.  
Modulated DSC was used to study the thermal properties of the OVA-adsorbed 
aluminum hydroxide dry powder. The DSC thermogram of the OVA-adsorbed aluminum 
hydroxide dry powder shows a glass transition temperature (Tg) of about 120oC (Fig. 3B), 
indicating that the OVA-adsorbed aluminum hydroxide particles suspended in trehalose 
solution may have formed a glass after subjected to TFFD (124). The high Tg value of 
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~120oC suggests that the OVA-adsorbed aluminum hydroxide dry powder is highly stable 
(125, 126). 
Shown in Fig. 3C is a representative SEM image of the OVA-adsorbed aluminum 
hydroxide dry powder. It appears that the OVA-adsorbed aluminum hydroxide particles, 
which have a rough surface and irregular shape (Fig. 3D), are embedded in the bulk 
structure of the trehalose (Fig. 3C inset). It is likely that the trehalose surrounding the OVA-
adsorbed aluminum hydroxide particles prevented the particles from interacting with one 



























Figure 2.3 Characterization of OVA-adsorbed aluminum hydroxide powder 
prepared with TFFD 
(A). The binding efficiency of OVA to AH gel before and after TFFD (inset, OVA protein 
band in SDS-PAGE gel). The binding efficiency was measured after the OVA-adsorbed 
AH gel was subjected to SDS-PAGE electrophoresis. (B). DSC curves of OVA-adsorbed 
AH gel dry powder, OVA, trehalose, and aluminum hydroxide alone. (C). A representative 
SEM image OVA-adsorbed AH gel dry powder. (D). A representative SEM image of the 




































(a) Trehalose, (b) OVA/AH gel powder, (c) OVA (d) AH gel  
 43 
2.3.4  The immunogenicity of the OVA-adsorbed aluminum hydroxide after 
thin-film freeze-drying 
To test whether the OVA-adsorbed aluminum hydroxide after subjected to TFFD 
retained its immunogenicity, the anti-OVA immune responses induced by OVA-adsorbed 
aluminum hydroxide, freshly prepared or reconstituted from TFFD powder, were evaluated 
in a mouse model. As shown in Fig. 4, the anti-OVA IgG levels in mice that were 
immunized with OVA-adsorbed aluminum hydroxide following TFFD and reconstitution 
were not different from that in mice that were immunized the freshly prepared OVA-
adsorbed aluminum hydroxide, regardless of the dose of OVA antigen used (i.e., 5, 10, or 
20 µg/mouse/injection). Clearly, the TFFD process not only avoided causing particle 
aggregation, but also preserved the immunogenicity of the OVA-adsorbed aluminum 







                                      
 
Figure 2.4 Serum anti-OVA IgG levels in mice immunized with OVA-adsorbed 
aluminum hydroxide, before and after TFFD and reconstitution  
Female BALB/c mice (n = 5) were s.c. injected with OVA-adsorbed AH gel, before or after 
it was subjected to TFFD and reconstitution, on days 0, 14 and 28 with 5 µg (A), 10 µg 
(B), or 20 µg (C) of OVA per mouse. The ratio of OVA to aluminum was 1 to 10. Sterile 
PBS and OVA alone (10 µg) in PBS were used as controls. Total anti-OVA IgG levels in 
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2.3.5  Thin-film freeze-drying of OVA-adsorbed aluminum phosphate and 
OVA-adsorbed Alhydrogel®  
Both aluminum hydroxide and aluminum phosphate are commonly used in human 
vaccines. Therefore, the feasibility of using TFFD to dry a protein antigen adjuvanted with 
aluminum phosphate into a powder was tested using OVA as a model antigen. Moreover, 
in the above studies, the aluminum hydroxide suspension (AH gel) was prepared in our 
own laboratories by dispersing dried aluminum hydroxide gel (USP grade) in water. 
Alhydrogel® (2%, w/v) is a commercially available aluminum hydroxide wet gel 
suspended in normal saline. Therefore, the feasibility of drying OVA-adsorbed 
Alhydrogel® using TFFD was also tested. Both OVA-adsorbed aluminum phosphate and 
OVA-adsorbed Alhydrogel® were successfully converted into powders using TFFD. Both 
dried samples appeared as light white-colored powder and were easily reconstituted in 
water with no or minimum agitation. The particle size distribution profiles of the OVA-
adsorbed aluminum phosphate before and after subjected to TFFD and reconstitution are 
shown in Fig. 5A, and the particle size distribution profiles of the OVA-adsorbed 
Alhydrogel® before and after subjected to TFFD and reconstitution are shown in Fig. 5B. 
Therefore, TFFD can be used to convert vaccines adjuvanted with aluminum phosphate or 








Figure 2.5 TFFD of OVA adjuvanted with aluminum phosphate or Alhydrogel®  
Shown are representative particle size distribution curves of OVA-adsorbed aluminum 
phosphate (A) and OVA-adsorbed Alhydrogel® (B) before and after they were subjected to 




2.3.6  Thin-film freeze-drying of a commercial veterinary tetanus toxoid 
vaccine, a human hepatitis B vaccine, and a human papillomavirus vaccine 
In order to further validate the applicability of the TFFD in drying vaccines 
adjuvanted with aluminum salts, the tetanus toxoid concentrated, adjuvanted detoxified 
toxin, a veterinary TT vaccine, Engerix-B, a human hepatitis B vaccine, and Gardasil, a 
human papillomavirus vaccine, were subjected to TFFD.  
The TT vaccine was diluted, and trehalose was added to a final concentration of 
2% (w/v) before the vaccine was subjected to TFFD. The particle size distribution profiles 
of the TT vaccine before and after being subjected to TFFD and reconstitution are shown 
in Fig. 6A. The mean diameter of the particles in the original vaccine was 23.1 ± 2.1 µm, 
and the mean particle size the TT vaccine reconstituted from the dried powder was 18.4 ± 
0.2 µm. Preliminary data showed that subjected undiluted TT vaccine in the presence of 
2% (w/v) of trehalose to TFFD and reconstitution did not cause particle aggregation as well 
(Thakkar & Cui, unpublished data). Clearly, subjecting the TT vaccine to TFFD and 
reconstitution did not cause significant aggregation.  
To investigate whether the TFFD process significantly altered the structure of the 
tetanus toxoid protein, the intrinsic fluorescence spectra of the TT vaccine before and after 
it was subjected to TFFD were acquired and compared. As shown in Fig. 6B, the 
fluorescence spectrum of the TT vaccine after it was subjected to TFFD and reconstitution 
only shifted slightly right (about 20 nm) when compared to the freshly diluted TT vaccine. 
In addition, the fluorescence intensity of the TT vaccine following TFFD and reconstitution 
was also relatively lower. Freeze-drying is known to perturb the structure of proteins at any 
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stage of the process, including freezing, drying, and reconstitution (67, 127, 128). The 
TFFD may have slightly altered the structure of the detoxified tetanus toxoid. However, it 
is unclear how the TFFD increased the polarity of the environment surrounding the 
tryptophan residues in the detoxified tetanus toxoid to induce a slight right shift in the 
spectra. When the immunogenicity of the TT vaccine before and after it was subjected to 
TFFD and reconstitution was evaluated and compared in a mouse model, the anti-tetanus 
toxin IgG levels determined using toxoid-ELISA in all the immunized groups were not 
significantly different (Fig. 6C). For anti-TT antibody responses, specific IgG levels 
measured using the toxoid-ELISA do not correlate well with tetanus toxin-neutralizing 
activity determined using in vivo toxin neutralization assay in mice or guinea pigs (117). 
However, it was shown that the ToBI-test is a reliable and precise alternative to the in vivo 
toxin neutralization assay, and there is a high degree of correlation between the ToBI-test 
and in vivo toxin neutralization assay (117). Therefore, the sera from mice immunized with 
the TT vaccine before and after it was subjected to TFFD and reconstitution were evaluated 
using the ToBI-test and compared. As shown in Fig. 6D, subjecting the TT vaccine to 
TFFD and reconstitution did not significantly affect the ToBI-test results. Although an in 
vivo toxin neutralization assay may ultimately have to be carried out to assess the effect of 
the TFFD on the toxin-neutralizing activity of the antiserum induced by the vaccine, data 
in Figs. 6C-D strongly indicated that the immunogenicity of the vaccine was not 
significantly decreased after it was subjected to TFFD and reconstitution.  
Engerix-B vaccine is a human hepatitis B vaccine, which contains human HBsAg 
adjuvanted with aluminum hydroxide (HBsAg to aluminum ratio, 1:25, w/w). To further 
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test the applicability of the TFFD process in drying commercially available vaccines 
adjuvanted with aluminum salts, trehalose powder was added directly into the Engerix-B 
vaccine to a final concentration of 2% (w/v) without further dilution, and the formulation 
was then subjected to TFFD. Shown in Fig. 7A are representative particle size distribution 
profiles of the Engerix-B vaccine before and after it was subjected to TFFD and 
reconstitution. The particle size of the Engerix-B after it was subjected to TFFD and 
reconstitution was 3.29 ± 0.15 µm, and particle size of the fresh Engerix-B vaccine was 
5.64 ± 0.01 µm. Gardasil is a human papillomavirus qaudrivalent vaccine that contains L1 
proteins from HPV 6, 11, 16, and 18 adjuvanted with amorphous aluminum 
hydrooxyphosphate sulfate (total L1 proteins to aluminum ratio, 1:1.875, w/w). It was 
diluted 10-fold (with a final trehalose concentration of 2% (w/v)) and then subjected to 
TFFD.  Shown in Fig. 7B are representative particle size distribution curves of the Gardasil 
before and after it was subjected to TFFD and reconstitution. Clearly, subjecting human 
Engerix-B vaccine or Gardasil vaccine to TFFD and reconstitution did not cause any 
significant aggregation. Therefore, it is likely that the TFFD method can be used as a 






 Figure 2.6 TFFD of tetanus toxoid vaccine 
(A) Representative particle size distribution curves of TT vaccine before and after it was 
subjected to TFFD and reconstitution. (B) Intrinsic tryptophan fluorescence spectra of TT 
vaccine before and after TFFD and reconstitution (C) Anti-tetanus toxin IgG levels in serum 
samples of mice immunized with TT vaccine before and after TFFD and reconstitution. (D) 
Inhibition of the binding of tetanus toxoid (to polyclonal horse anti-tetanus antiserum by the 
antisera from immunized mice). Female BALB/c mice (n = 5) were s.c. injected with TT 
vaccine, before or after TFFD and reconstitution, on days 0, 14 and 28 with 3.75 Lf of tetanus 
toxoid per mouse per injection. Sterile PBS and original TT vaccine diluted in sterile PBS 
(original TT) or 2% trehalose (TT in trehalose) were used as controls. Mice were bled 16 days 






Figure 2.7 TFFD of Engerix-B and Gardasil  
Shown are representative particle size distribution curves of Engerix-B (A) or Gardasil (B) 
vaccines before and after they were subjected to TFFD and reconstitution. Engerix-B was 
subjected to TFFD in 2% of trehalose without further dilution. Gardasil was diluted 10-
time and then subjected to TFFD in 2% of trehalose.  
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2.3.7 Stability of vaccine dry powder after repeated freezing-and-thawing 
To test whether vaccines that are converted to dry powder using TFFD are still 
sensitive to inadvertent freezing (and thawing), dried powders of TT vaccine, Engerix-B 
vaccine, and OVA-adjuvanted Alhydrogel® (OVA/Alhydrogel®) were subjected to three 
cycles of freezing-and-thawing and then reconstituted. As a control, fresh vaccines that 
were not subjected to TFFD were also subjected to the same freezing–and-thawing cycles. 
As shown in Fig. 8, repeated freezing-and-thawing of all three vaccines in suspension 
caused significant aggregations, whereas subjecting the dried powders of the same vaccines 
to the same freezing-and-thawing cycles did not cause any significant aggregation. It 
appears that unlike liquid vaccines that are adjuvanted with aluminum salts, the same 
vaccines that are converted to dry powders using the TFFD were not sensitive to freezing 
conditions anymore. Therefore, converting a vaccine that contains an aluminum salt as 
adjuvant from liquid to dry powder using TFFD is expected to help avoid the loss of 
vaccines resulted from unintentionally exposing the vaccine to freezing temperatures 
during shipment or storage (46, 110). Experiments to evaluate and compare the immune 
responses induced by thin-film freeze-dried vaccine powder before and after it is subjected 
to multiple cycles of freezing-and-thawing (and reconstitution) are currently underway.  
As mentioned earlier, vaccines adjuvanted with aluminum salts were successfully 
converted to dry powder by various methods including spray drying (63), spray freeze-
drying (63, 67-69), and standard tray freeze-drying (67-69, 129). However, data in the 





Figure 2.8 Freezing-and-thawing of vaccine dry powder 
 
 
A. TT vaccine 




Figure 2.8 (continued) 
Shown are representative particle size distribution curves of TT vaccine (A), Engerix B 
(B), and OVA adjuvanted with Alhydrogel (OVA/Alhydrogel) (C), before and after the 
thin-film freeze-dried powders were subjected to 3 cycles of freezing-and-thawing and 
then reconstitution (i.e., TFFD vs. TFFD, after freeze thaw). As a control, the particle 
size distribution curve of the respective fresh vaccines (i.e., FV) and the fresh vaccines 










immunogenicity of the vaccines (63, 67-69). They are rather methods of preparing 
immunologically-active aluminum salt-adjuvanted dry vaccines, albeit with reduced 
immunogenicity (69). The thin-film freeze-drying method used in the present study 
represents a method that converts vaccines adjuvanted with aluminum salts from a liquid 
suspension to a dry powder without causing particle aggregation or damage to the 
immunogenicity of the vaccines. In TFF process, liquid droplets fall from a given height 
above a cryogenically cooled metal surface (70). Upon impact, the droplets spread out into 
thin films of 100-400 µm that froze on a time scale of 70-1,000 ms, which corresponding 
to a cooling rate of about 100 K/s (70, 130-135). The rapid cooling/freezing explains why 
the particle size (distribution) and the immunogenicity of vaccines adjuvanted with 
aluminum salts were not significantly changed after they are subjected to TFFD and 
reconstitution, as it was reported that fast freezing can minimize particle coagulation and 
thus maximizing the immunogenicity of vaccines adjuvanted with aluminum salts (63, 68, 
69). However, in the previously reported spray freeze-drying method, when atomized 
vaccine droplets were dropped above liquid nitrogen, they traveled through the cold gas 
above the cryogenic liquid nitrogen and completely froze at an estimated cooling rate of 
about 106 K/s after contacting the liquid nitrogen (136). In other words, the cooling rate 
during spray freezing is in theory much higher than during the TFFD process. It is thus 
surprising that in previous reports, aluminum salt-adjuvanted vaccines after subjected to 
spray freeze-drying and reconstitution did not maintain their particle size and/or 
immunogenicity (63, 67-69).  
 56 
Besides cooling rate, low aluminum salt concentration and high excipient levels are 
also indicated as two important parameters that help minimize vaccine aggregation and 
maximize the immunogenicity of vaccines (63, 68). In the present study, the concentrations 
of the aluminum hydroxide in the vaccine formulations we prepared ranged from 0.09% to 
~1% (w/v).  The concentration of aluminum in the Engerix-B was ~0.5 mg/ml, 0.045 
mg/ml in the diluted Gardasil (the concentration of aluminum in the TT vaccine is 
unknown). It was found that trehalose as a single excipient at 2% (w/v) was sufficient to 
help maintain the particle size (distribution) and immunogenicity of the vaccines during 
the TFFD and reconstitution process. In previous spray freeze-drying studies, the 
aluminum hydroxide concentration was 0.2% (w/v) (67-69) or 0.6% (w/v) (63). Aluminum 
hydroxide at a final concentration of 3% (w/v) was also tested, but the immunogenicity of 
the resultant powder after reconstitution was significantly decreased (i.e., 10-fold lower 
than that of the original liquid vaccine) (63). The concentration of trehalose as a single 
excipient was 7.5% (w/v) or above (67-69), and in Maa et al.’s study, the excipient was 
comprised of mannitol, dextran, and glycine (63). Yet, the particle size and/or 
immunogenicity of the vaccines changed after subjected to spray freeze-drying and 
reconstitution (63, 67-69).   
Therefore, fast cooling rates, low aluminum salt concentrations, and high excipient 
levels are critical factors/parameters in minimizing vaccine aggregation and maximizing 
the immunogenicity of vaccines during freeze-drying. However, other factor(s) may also 
play an important role in maintaining the particle size and immunogenicity of aluminum 
salt-adjuvanted vaccines during freeze-drying and reconstitution. For example, the 
 57 
antigens used in the freeze-drying process may be critical. Lysozyme, alkaline 
phosphatase, BoNT/E, BoNT/C, and HBsAg were used previously in spray freeze-drying 
studies (63, 67-69). In the present study, OVA and tetanus toxoid (in a veterinary TT 
vaccine) were used. The aluminum hydroxide-adjuvanted HBsAg, Engerix-B, and the 
aluminum hydrooxyphosphate sulfate-adjuvanted HPV L1 proteins, Gardasil, were also 
subjected to TFFD, but the immunogenicity of the vaccines after subjected to TFFD and 
reconstitution was not tested yet. More importantly, however, it is known that during spray 
freeze-drying, the large gas-liquid interface in the spraying step causes protein 
aggregations (136-138). The TFF process freezes liquid droplets dropped on the 
cryogenically cooled metal surface in relatively lower cooling rates, but the much smaller 
area of the air-liquid interface of the falling droplets and the spread film, in comparison to 
the atomized droplets in spray freeze-drying (70), may have contributed to the ability of 
the TFFD process to convert liquid aluminum salt-adjuvanted vaccine to dried powder 










2.4      CONCLUSION 
Vaccines that are adjuvanted with aluminum salts can be successfully converted 
from liquid suspension into dry powder by thin-film freeze-drying using a relatively low 
concentration of trehalose (2%, w/v) as an excipient, without causing particle aggregation 
or decrease in the immunogenicity of the vaccines. In addition, the dry vaccine powder did 
not aggregate after repeated freezing-and-thawing. It is expected that this thin-film freeze-
drying method can be used to formulate new vaccines, or to reformulate existing vaccines, 

















The Immunogenicity of thin-film freeze-dried, aluminum salt-
adjuvanted vaccine when exposed to different temperatures2 
3.1       INTRODUCTION 
 
Some insoluble aluminum salts, e.g. aluminum oxyhydroxide and aluminum 
hydroxyphosphate, have been widely used as human vaccine adjuvants for decades, and 
many currently licensed and commercially available vaccines, including those for 
diphtheria-tetanus-pertussis, hepatitis A and B, pneumococcal disease, anthrax, and rabies, 
contain aluminum salts as adjuvants (139-141). The primary particles of aluminum 
oxyhydroxide and aluminum hydroxyphosphate are in the nanometer range. However, 
when dispersed in an aqueous solution, these particles aggregate to form large 
microparticles (e.g. 1-20 µm) (141, 142). Thus, a vaccine that is prepared by binding an 
antigen onto an aluminum salt is physically a liquid suspension of aluminum salt particles 
with antigens adsorbed on them.  
Protein antigens adsorbed on aluminum salt adjuvants in liquid suspension are 
generally too fragile to be stable in ambient temperatures. Also, exposing the liquid 
suspension of aluminum salt-adjuvanted vaccines to slow freezing causes irreversible 
aggregation of the aluminum salt particles that damages the vaccines (e.g. permanent loss 
                                                 
2 This chapter is based on “Sachin G. Thakkar, Tinashe B Ruwona, Robert O. Williams III, Zhengrong 
Cui, Human Vaccines & Immunotherapeutics, January 2017, Vol. 13, No. 4, 936–946  
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in potency and/or effectiveness) (60, 143-147). Because of these reasons, aluminum salt-
adjuvanted vaccines must be maintained in cold-chain (i.e. 2-8o C) during production, 
handling, transport, storage, and use (148). Unfortunately, published reports and field 
evidence demonstrate that inadvertent freezing of vaccines during transport and storage in 
cold-chain is a commonplace, and not resource limited (110, 146, 149-153). This in effect 
causes the widespread delivery of vaccines with compromised potency, which could result 
in unintentional administration of suboptimal vaccines to patients (145, 154-158), and/or 
costly waste of global vaccine supplies (48, 150), Meanwhile, as the costs and/or logistical 
constraints of vaccine delivery associated with the cold-chain requirements significantly 
obstructs global vaccine access, there is increasing interest in novel approaches to vaccine 
stability management such as controlled temperature chain (CTC) storage (45, 46). CTC 
allows vaccines to be managed in temperatures outside of the traditional cold-chain for a 
limited period of time, typically a single excursion into ambient temperature not exceeding 
40° C for the duration of a specific number of days prior to administration (47). For 
example, in 2012, MenAfriVacTM became the first to be prequalified by the World Health 
Organization (WHO) to receive regulatory approval during mass vaccination that allowed 
vaccine storage at or below 40° C for up to 4 days (45, 48, 49). It is estimated that by using 
CTC, the costs of using cold-chain and the associated logistics can be reduced by 50% (48).  
Thin-film freeze-drying (TFFD) is a rapid freezing technology originally studied to 
enhance the solubility of poorly water-soluble compounds, and was recently used to 
prepare stable submicron protein particles (70, 111). In the process of TFFD, droplets of 
drug formulation are rapidly frozen upon impact with a cryogenically-cooled substrate to 
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form thin films in less than a second. These thin films are then lyophilized to remove 
solvent in the formulation (111). Previously, we reported that vaccines adjuvanted with 
aluminum salts can be successfully converted from liquid suspension to dry powder by 
TFFD, without causing particle aggregation or decreasing in immunogenicity following 
reconstitution (159). In an effort to test whether converting vaccines adjuvanted with 
aluminum salts from liquid suspension to solid dry powder can afford managing the 
vaccines in CTC, here we tested the stability of a thin-film freeze-dried, aluminum 
oxyhydroxide-adjuvanted vaccine powder. The stability of the dry vaccine powder was 
evaluated in temperatures as high as 40° C for up to 6 months by measuring the particle 
size distribution and the immunogenicity of the vaccine powder upon reconstitution. 
Moreover, as the risk of unintentional exposure of vaccines to freezing temperatures 
remains regardless whether the vaccines are managed in cold-chain or CTC, or by any other 
approaches, we also tested the immunogenicity of a thin-film freeze-dried, aluminum 
oxyhydroxide-adjuvanted vaccine powder after it was subjected to repeated slow freezing-
and-thawing cycles (and then reconstitution) in a mouse model. Data from our previous 
study showed that subjecting thin-film freeze-dried, aluminum salt-adjuvanted vaccines to 
repeated slow freezing-and-thawing cycles does not cause particle aggregation upon 
reconstitution (159).   
Commercial vaccines usually contain additional excipients such as buffer, 
stabilizer(s), and preservative(s) that are unique and often proprietary to each vaccine and 
could potentially protect the vaccines from freezing or heat stress to a certain degree. 
Therefore, in the present study, we prepared a model vaccine by adsorbing ovalbumin 
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(OVA) as a model antigen onto Alhydrogel®, i.e. aluminum oxyhydroxide (2%, w/v), and 
used it for the immunogenicity evaluations. It is known that freezing or heating OVA 
denatures the protein (160, 161), and denatured OVA is less immunogenic than native 
OVA and has different immunogenic epitopes (162, 163). There are also reports that certain 
excipients such as high concentrations of phosphate (e.g. 40 or 100 mM) and histidine can 
help improve the thermal stability of vaccine, and polyols such as propylene glycol, 
polyethylene glycol 300, and glycerol can help make vaccine insensitive to freezing (164-
166). In this study, the OVA-adsorbed Alhydrogel® liquid vaccine was prepared in the 
absence of those excipients, making it ideal, in our opinion, for the present study. The 
OVA-adsorbed Alhydrogel® dry powder was prepared by TFFD using OVA-adsorbed 





















3.2       MATERIALS AND METHODS 
3.2.1 Preparation of OVA-adsorbed Alhydrogel® vaccine dry powder  
The OVA-Alhydrogel® vaccine was prepared by adding 25 mL of Alhydrogel® (2% 
w/v, or 10 mg/mL aluminum, manufactured by Brenntag, and supplied by InvivoGen, San 
Diego, CA) into a 50 mL tube followed by the addition of 25 mL of an OVA solution (1 
mg/mL in phosphate-buffered saline (PBS), pH 7.4, 10 mM, Sigma-Aldrich, St. Louis, 
MO) and 1 g of trehalose (as a cryoprotectant) (Sigma-Aldrich) to obtain a final 
formulation with 2% (w/v) of trehalose, ~1% (w/v) of Alhydrogel®, and 0.5 mg/mL of 
OVA, with a low 5 mM concentration of PBS. The size and size distribution of the OVA-
adsorbed Alhydrogel® in suspension was determined using a Sympatec Helos laser 
diffraction instrument equipped with an R3 lens (Sympatec GmbH, Germany). The vaccine 
suspension was converted into a dry powder using our previously reported thin-film freeze-
drying method (70, 111, 159). The powder was dried using a VirTis AdVantage Bench Top 
Lyophilizer (The VirTis Company, Inc. Gardiner, NY). Lyophilization was performed over 
72 h at pressures less than 200 mTorr, while the shelf temperature was gradually ramped 
up from −40° C to 26° C. After lyophilization, the solid dry vaccine powder was transferred 
into a sealed container and stored in a desiccator (112). The moisture content in the dried 
powder was determined using a Karl Fisher Titrator Aquapal III from CSC Scientific 
Company (Fairfax, VA). 
 To test the feasibility of preparing dry vaccine powder by thin-film freeze-drying 
in a single vial, silanized glass vials were used to provide the cryogenic surface for rapidly 
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freezing the liquid vaccine. Glass vials were submerged into liquid nitrogen to make the 
cryogenic surface, with the mouth and neck of the vials remaining in the air (not 
submerged). Using a pipette or syringe, the OVA/Alhydrogel® vaccine liquid suspension 
with 2% of trehalose (w/v) (0.25-0.5 mL) was added drop wise into the glass vials. Thin 
films of vaccine were quickly formed by ultra-rapid freezing on the inner surface of the 
vial, which were then lyophilized as mentioned above. After lyophilization, the glass vials 
were quickly crimped, transferred to a sealed container, and stored in a desiccator in room 
temperature before further use. As a control, OVA/Alhydrogel® vaccine liquid suspension 
in a glass vial was placed on the shelf on the lyophilizer. The shelf temperature was 
gradually decreased from room temperature to -40° C, and then ramped from −40° C to 26° 
C over 72 h at pressures of less than 200 mTorr. To test whether the above mentioned 
freeze-drying method significantly affected the particle size distribution of the vaccine, the 
lyophilized dry vaccine powder was reconstituted using water. The particle size and 
particle size distribution were determined using a Sympatec Helos laser diffraction 
instrument. As controls, the particle size distribution profiles of freshly prepared 
OVA/Alhyrogel® vaccine and the same OVA/Alhydrogel® vaccine that was subjected to 
TFFD using the  previously reported method and then reconstitution were also evaluated 
(159).  
 3.2.2 Stability study 
The OVA/Alhydrogel® dry powder was crimp-sealed with aluminum seals over 
rubber lids in silanized glass vials, which were then stored in desiccators placed in room 
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temperature (i.e. 22-24° C) or in incubators (30° C or 40° C). As a control, 
OVA/Alhydrogel® liquid suspension that was crimp-sealed with aluminum seals over 
rubber lids in silanized glass vials was also stored at 4° C, room temperature, 30° C, and 
40° C. At various time points (i.e. 1, 3, or 6 months later), the particle size and size 
distribution of the vaccine, in liquid suspension or reconstituted from dry powder, were 
determined using a Sympatec Helos laser diffraction instrument. The immunogenicity of 
the vaccine was evaluated in a mouse model.  
3.2.3 Chemical stability of the OVA protein desorbed from OVA/Alhydrogel®  
SDS-PAGE electrophoresis was used to evaluate the chemical integrity of the OVA 
desorbed from Alhydrogel® after storage as mentioned above. Briefly, OVA/Alhydrogel® 
dry vaccine powder containing 1 mg of OVA was reconstituted and incubated in the 
presence of sodium citrate (Sigma-Aldrich) to a final concentration of 10% (w/v) at 37° C 
overnight. The samples were then centrifuged to collect the supernatant. Control samples 
included reconstituted OVA-adsorbed Alhydrogel® incubated similarly but in the absence 
of sodium citrate, freshly prepared OVA/Alhydrogel®, and OVA alone. Samples were 
mixed with a Laemmli sample buffer (Sigma-Aldrich) before applied to 7.5% Mini-
PROTEAN® TGX™ precast polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA). 
Precision plusTM protein standards (Bio-Rad) were also run along with the samples at 130 
V for 1 h. The gels were then stained in a Bio-SafeTM Coomassie blue staining solution and 
scanned using a Kodak Image Station 440CF (Rochester, NY).  
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3.2.4 Repeated freezing-and-thawing studies 
Thin-film freeze-dried OVA/Alhydrogel® powder was placed at -20° C for 8 h and 
then thawed at 4° C for 16 h for three cycles. After the third cycle, the dry powder was 
reconstituted to (i) measure its particle size and size distribution using a Sympatec Helos 
laser diffraction instrument and (ii) evaluate its immunogenicity in a mouse model. As a 
control, OVA/Alhydrogel® vaccine in liquid suspension was also subjected to 3 cycles of 
freezing-and-thawing, and its particle size distribution and immunogenicity were 
evaluated.  
3.2.5  Animal studies 
All animal studies were conducted following the U.S. National Research Council 
Guide for the Care and Use of Laboratory Animals. The Institutional Animal Care and Use 
Committee at The University of Texas at Austin approved the animal protocol. Female 
BALB/c mice, 6-8 weeks of age, were from Charles River Laboratories, Inc. (Wilmington, 
MA). Mice (n = 5) were subcutaneously (s.c.) injected with OVA/Alhydrogel®, freshly 
prepared, after storage, or after freezing-and-thawing cycles. Mice were immunized on 
days 0, 14, and 28, and the dose of OVA was 5 μg per mouse. As controls, mice were s.c. 
injected with sterile PBS or OVA alone in PBS. Sixteen days after the third dose, mice 
were bled, and the anti-OVA IgG levels in serum samples were determined using enzyme-
linked immunosorbent assay (ELISA) (116). Briefly, EIA/RIA flat bottom, NUNC 
Maxisorp, 96-well plate (Thermo Fisher) were coated with 1 ng/μl of OVA solution in 
carbonate buffer (0.1 M, pH 9.0) overnight at 4° C. Plates were blocked with horse serum 
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for one hour before adding the blood serum. Horse radish peroxidase (HRP)-labeled goat 
anti-mouse immunoglobulin (IgG, 5000-fold dilution, Southern Biotechnology Inc., 
Birmingham, AL) was added into the plates, and the presence of bound antibody was 
detected in the presence of 3,3′,5,5′-tetramethylbenzidine solution (TMB, Sigma–Aldrich). 
The absorbance was read at 450 nm. 
3.2.6 Statistics 
Statistical analyses were conducted using analysis of variance followed by 
Fischer’s protected least significant difference procedure. A p-value of < 0.05 (two-tail) 














3.3 RESULTS AND DISCUSSION   
Previously, we reported that vaccines adjuvanted with an insoluble aluminum salt, 
e.g. aluminum oxyhydroxide, aluminum hydroxyphosphate, or amorphous aluminum 
hydroxyphosphate sulfate, can be converted from liquid suspension to dry powder without 
causing particle aggregation or decreasing in immunogenicity following reconstitution 
(159). In the present study, we tested whether an aluminum salt-adjuvanted vaccine powder 
prepared by TFFD could be a potential candidate for CTC. CTC allows a single excursion 
into ambient temperature not exceeding 40° C for the duration of a specific number of days 
prior to administration. Therefore, we evaluated the immunogenicity of a model vaccine 
prepared by adsorbing OVA as a model antigen onto Alhydrogel® after it was converted to 
a dry powder by TFFD in the presence of 2% (w/v) of trehalose and then stored in 
temperatures as high of 40° C for up to 6 months. OVA was adsorbed onto Alhydrogel® at 
an OVA to aluminum ratio of 1:10 (w/w, with ~100% antigen adsorption, data not shown). 
3.3.1 Stability of OVA/Alhydrogel® liquid vaccine 
Initially, we evaluated the immunogenicity of the OVA/Alhydrogel® vaccine in 
liquid suspension (with 2% trehalose, w/v, to keep the composition identical to that in the 
dry vaccine powder). The liquid suspension was stored at 4° C, room temperature, 30° C, 
and 40° C for 3 months, and the particle size and size distribution of the vaccine were 
determined 1 and 3 months later. Shown in Figs. 1A-B are representative particle size 
distribution curves of the OVA/Alhydrogel® vaccine liquid suspension after 1 month (Fig. 
1A) or 3 months (Fig. 1B) of storage in various temperatures. The representative particle 
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size distributions, expressed as X10, X50, and X90 of the OVA/Alhydrogel
® vaccine liquid 
suspension after 1 month or 3 months of storage in various temperatures, are shown in 
Table 1. X10, X50, and X90 denote particle dimensions corresponding to 10%, 50%, and 
90% of the cumulative undersize distribution. Aggregation was minimal after 1 month of 
storage, but became apparent after 3 months, as can be seen by the increase in X90 values 
(Fig. 1B, and Table 1). For example, the X90 values of the liquid vaccine suspension stored 
at 30° C increased from ~10 µm to ~42 µm (Table 1). For the liquid vaccine suspension 
stored at 30° C, there is a slight decrease in the X10 and X50 values from 1 month to 3 
months of storage, but the X90 values are increased, indicating that smaller size particles 
aggregated to form bigger particles. This increase in X90 values skews the particle size 
distribution to the right. However, it is not clear why there was a slight decrease in the 
particle size for the OVA/Alhydrogel® liquid vaccine stored at 40° C (Table 1).  
To evaluate the immunogenicity of the OVA/Alhydrogel® vaccine liquid 
suspension after 3 months of storage in room temperature or 4° C, mice were immunized 
(s.c.) with it, and the serum anti-OVA IgG levels induced were compared to that induced 
by freshly prepared OVA/Alhydrogel® vaccine liquid suspension. As shown in Fig. 1C, 
storing the OVA/Alhydrogel® vaccine liquid suspension in room temperature for 3 months 
led to significantly reduced anti-OVA IgG response, as compared to freshly prepared 
OVA/Alhydrogel® vaccine liquid suspension (Fig. 1C). We did not test the 
immunogenicity of the OVA/Alhydrogel® liquid vaccine stored at 30° C and 40° C because 
the vaccine does not contain any excipient that is known to improve the thermal stability 
of vaccines, which could explain the decrease in immunogenicity even when the liquid 
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vaccine was stored at 4° C (Fig. 1C). This is critical as there are aluminum salt-adjuvanted 
vaccines in liquid suspension that were reported to be stable at elevated temperatures (e.g. 
HavrixTM is stable at 37° C for 3 weeks; NeisVac-CTM is stable at 40° C for 1 month).(167-
170) Therefore, the OVA/Alhydrogel® vaccine is a good candidate for us to test the 
immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine dry powder 
when exposed to temperatures outside the cold-chain. Data from a previous study reported 
that high concentrations of phosphate ion (> 40 mM) increase the thermal stability of 
aluminum oxyhydroxide-adjuvanted hepatitis B vaccine (165). When preparing the OVA-
adsorbed Alhydrogel® vaccine, we dissolved the OVA in a low concentration of PBS, and 
the final PBS concentration in the OVA/Alhydogel® liquid vaccine was 5 mM. As 
expected, the low concentration phosphate ion did not render the liquid vaccine 
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Figure 3.1 (Continued) 
Representative particle size distribution curves of OVA/Alhydrogel® vaccine liquid 
suspension after 1 month (A) and 3 months (B) of storage in various temperatures. The 
experiment was carried out with three replicates with similar results (RT, room 
temperature; FV, fresh vaccine). (C) Serum anti-OVA IgG levels in mice immunized with 
OVA/Alhydrogel® liquid vaccine that was stored in 4° C or room temperature for 3 months. 
As controls, mice were injected with sterile PBS or freshly prepared OVA/Alhydrogel® 
vaccine (i.e. Fresh vaccine). Female BALB/c mice (n = 5) were injected (s.c.) on days 0, 
14, and 28 with 5 μg of OVA per mouse. Total anti-OVA IgG levels in serum samples 
were measured about three weeks after the third dose. Data are mean ± S.D. (* p < 0.05, 







Liquid vaccine 1 month X10 (µm) X50 (µm) X90 (µm) 
OVA/Alhydrogel®, FV  1.56 ± 0.07 4.29 ± 0.68 10.77 ± 3.46 
OVA/Alhydrogel®, RT 1.3 ± 0.04 3.03 ± 0.09 8.59 ± 1.57 
OVA/Alhydrogel®, 4° C 1.65 ± 0.08 4.5 ± 0.66 10.35 ± 2.98 
OVA/Alhydrogel®, 30° C 1.41 ± 0.04  3.23 ± 0.17 9.25 ± 1.56 
OVA/Alhydrogel®, 40° C 1.5 ± 0.04 3.86 ± 0.55 9.25 ± 2.07 
 
(B) 
Liquid vaccine 3 month X10 (µm) X50 (µm) X90 (µm) 
OVA/Alhydrogel®, FV  1.56 ± 0.07 4.29 ± 0.68 10.77 ± 3.46 
OVA/Alhydrogel®, RT 1.23 ± 0.05 3.19 ± 0.15 24.81 ± 15.07 
OVA/Alhydrogel®, 4° C 1.35 ± 0.05 3.23± 0.16 17.38 ± 8.35 
OVA/Alhydrogel®, 30° C 1.20 ± 0.06  3.07 ± 0.24 41.56 ± 23.29 
OVA/Alhydrogel®, 40° C 1.04 ± 0.25 2.37 ± 0.51 6.38 ± 0.72 
Table 3.1  Effect of storage temperatures on the particle size and size distribution 
of OVA/Alhydrogel® liquid vaccine suspension 
Representative particle size distribution numbers expressed as X10, X50, and X90 of the 
OVA/Alhydrogel® vaccine liquid suspension after 1 month (table 1A) or 3 months (table 
1B) of storage at various temperatures. Data are mean ± S.D. (n ≥ 3). X10, X50, and X90 





3.3.2 Stability of OVA/Alhydrogel® vaccine dry powder 
We then stored the thin-film freeze-dried OVA/Alhydrogel® vaccine powder in 
room temperature, 30° C, and 40° C. The dry powder was reconstituted 1, 3, and 6 months 
later to evaluate the particle size and size distributions, and/or the immunogenicity of the 
vaccine. Shown in Fig. 2 are representative particle size distribution curves of the 
OVA/Alhydrogel® vaccine reconstituted from thin-film freeze-dried powder that was 
stored in room temperature, 30° C, or 40° C for 1 month (Fig. 2A), 3 months (Fig. 2B), or 
6 months (Fig. 2C), respectively. Particle aggregation was not detected after 1 month of 
storage in all three temperatures (Fig. 2A, Table 2). Slight particle aggregation was 
detected after 3 months of storage at 40° C, as can be seen by the increase of X90 values 
from 20 µm to 51 µm (Fig. 2B, Table 2). After 6 months of storage, particle aggregation 
became noticeable in all three temperatures, especially 40° C (Fig. 2C, Table 2). Similar to 
the particle size distribution in the liquid vaccine after storage, the increase in the particle 
size in the dry powder after storage can be seen in the X90 values only. This is likely because 
as the particles aggregate, there is a slight increase in the X90 value. An increase in the X50 
value would indicate the aggregation is more severe, as will be showed in the case of 
subjecting the vaccine to repeated freezing-and-thawing cycles in a later section.  
The chemical stability of the OVA antigen in the OVA/Alhydrogel® vaccine dry 
powder was also monitored. SDS-PAGE data show that after the OVA/Alhydrogel® 
vaccine dry powder was stored for 1 month in different storage temperatures, the OVA 
desorbed from the OVA/Alhydrogel® dry powder was similar to the OVA desorbed from 
freshly prepared OVA/Alhydrogel® liquid suspension (data not shown). However, after 6 
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months of storage, especially at 40° C, the band intensity of the OVA desorbed from the 
OVA/Alhydrogel® dry powder became much weaker than that desorbed from freshly 
prepared OVA/Alhydrogel® liquid suspension (data not shown), which may be attributed 
to protein chemical degradation and/or decreased desorption of OVA from Alhydrogel® 
due to tight binding. There are reports that storing vaccines for an extended period of time 
may increase the tightness of the binding of the antigens to Alhydrogel® (171-173).  
Shown in Fig. 3 are the anti-OVA IgG levels in mice that were immunized with 
OVA/Alhydrogel® vaccine reconstituted from dry powder that was stored in various 
temperatures for 1 month (Fig. 3A) or 3 months (Fig. 3B). Clearly, after 3 months of 
storage, the serum anti-OVA IgG levels in mice immunized with OVA/Alhydrogel® 
reconstituted from the thin-film freeze-dried powder were not significantly different from 
that induced by freshly prepared OVA/Alhydrogel® vaccine (Fig. 3). Also, the serum anti-
OVA IgG levels for the dry vaccine powders stored for 1 month and 3 months are not 
different. Due to the physical and chemical instability (e.g. particle aggregation, potential 
antigen degradation) detected after the OVA/Alhydrogel® dry powder was stored in 
various temperatures, especially at 40° C, it became unnecessary to test the 
immunogenicity of the vaccine dry powder after 6 months of storage.  
It was previously reported that converting vaccines from liquid to dry powder can 
render the otherwise fragile vaccine stable in ambient temperatures (129, 174-179). The 
OVA/Alhydrogel® particles in the thin-film freeze-dried powder are embedded in a glass 
of trehalose with a glass transition temperature (i.e. Tg) of 120° C. The Tg is significantly 
higher than highest temperature (i.e. 40° C) in which the vaccine dry powder was stored, 
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allowing the vaccine to remain in a low-mobility, glassy state. However, it is worth 
pointing out that in the present study, while the temperatures in which the 
OVA/Alhydrogel® vaccine was stored was controlled, the moisture content in the powder 
increased with the extended period of storage, and was higher in higher temperature. For 
example, after 3.5 months of storage, the moisture content in the powders stored at 40° C, 
30° C, and room temperature increased from the initial value of 1-3% to 7.7 ± 1.9%, 6.0 ± 
0.9%, 5.4 ± 0.5%, respectively (n = 6-9, p < 0.05, values at 40° C vs. in room temperature). 
It is thus expected that the vaccine dry powder may potentially be stored in room 
temperature or above for a longer period of time, if the moisture content of the dry powder 
is better controlled during storage (129). Alternatively, an excipient that is less hygroscopic 
than trehalose and has a higher Tg value, e.g. dextran, could be potentially used to improve 
the storage stability (176). For instance, recently Kunda et al. showed that modified 
packaging system (inert N2 gas, oxygen scavengers, and desiccant sachet) can be used to 
control the moisture content to increase the stability of the dry powder vaccines in elevated 
temperatures (180). Nonetheless, data in Figure 3 show that thin-film freeze-drying offers 
a potentially viable approach to manage aluminum salt-adjuvanted vaccines in CTC, 
because exposing the thin-film freeze-dried vaccine powder to temperatures as high as 40° 
C for up to 3 months did not cause significant decrease in the immunogenicity of the 








Figure 3.2 Effect of temperature on particle size distribution of the 
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Figure 3.2 (Continued) 
Representative particle size distribution curves of OVA/Alhydrogel® vaccine dry powder 
after stored in various temperatures for 1 month (A), 3 months (B), and 6 months (C) and 
then reconstituted (TFFD, thin-film freeze-dried vaccine powder; RT, room temperature; 



































TFFD 1 month  X10 (µm) X50 (µm) X90 (µm) 
OVA/Alhydrogel®, FV   2.36 ± 0.005 6.37 ± 0.02 13.79 ± 0.11 
OVA/Alhydrogel®, RT  2.14 ± 0.02 5.96 ± 0.46 15.39 ± 2.54 
OVA/Alhydrogel®, 30° C  1.97 ± 0.21  5.44 ± 0.87 13.89 ± 3.42 




TFFD 3 month X10 (µm) X50 (µm) X90 (µm) 
OVA/Alhydrogel®, FV  2.36 ± 0.005 6.37 ± 0.02 13.79 ± 0.11 
OVA/Alhydrogel®, RT 1.73 ± 0.05 4.76 ± 0.06 15.28 ± 0.55 
OVA/Alhydrogel®, 30° C 1.95 ± 0.04  6.29 ± 0.31 28.24 ± 15.39 




TFFD 6 month X10 (µm) X50 (µm) X90 (µm) 
OVA/Alhydrogel®, FV  2.36 ± 0.005 6.37 ± 0.02 13.79 ± 0.11 
OVA/Alhydrogel®, RT 1.10 ± 0.01 3.78 ± 0.36 16.44 ± 5.01 
OVA/Alhydrogel®, 30° C 2.19 ± 0.03  6.86 ± 0.18 30.04 ± 5.49 
OVA/Alhydrogel®, 40° C 2.20 ± 0.32 7.53 ± 1.75 47.03 ± 44.14 
Table 3.2  Effect of storage temperatures on the particle size and size distribution 
of OVA/Alhydrogel® dry vaccine powder 
Representative particle size distribution numbers expressed as X10, X50, and X90 of the 
OVA/Alhydrogel® dry vaccine powder after 1 month (table 2A), 3 months (table 2B), or 6 
months (table 2C) of storage at various temperatures. Data are mean ± S.D. (n ≥ 3). X10, 
X50, and X90 denotes to particle dimensions corresponding to 10, 50, and 90% of the 




Figure 3.3  Effect of temperature on the immunogenicity of the dry vaccine powder 
Serum anti-OVA IgG levels in mice immunized with OVA/Alhydrogel® vaccine dry 
powder that was stored at 40° C, 30° C, or room temperature for 1 month (A) or 3 months 
(B) and then reconstituted. As controls, mice were injected with sterile PBS or freshly 
prepared OVA/Alhydrogel® vaccine (i.e. Fresh vaccine). Female BALB/c mice (n = 5) 
were injected (s.c.) on days 0, 14, and 28 with 5 μg of OVA per mouse. Total anti-OVA 
IgG levels in serum samples were measured about three weeks after the third dose. Data 






3.3.3 Stability of OVA/Alhydrogel® dry powder vaccine to freezing 
The risk of exposing a vaccine to freezing temperatures during transport and/or 
storage exists regardless whether the vaccine is managed in cold-chain, CTC, or in ambient 
temperatures. Converting aluminum salt-adjuvanted vaccines from a liquid suspension to 
dry powder by thin-film freeze-drying is expected to render the vaccine insensitive to 
freezing. The OVA/Alhydrogel® particles in the thin-film freeze-dried powder are 
embedded in a glass of trehalose with a Tg value of 120° C (159). Trehalose limits the 
mobility of the aluminum salt particles by forming glass during freezing (122), and we 
have previously shown using transmission electron microscopy that the OVA-adsorbed 
aluminum hydroxide particles are embedded in the bulk structure of trehalose, which likely 
prevents the particles from interacting with one another during freeze-drying process.(159) 
Similarly, the trehalose glass is expected to make it difficult, if possible, for any subsequent 
slow freezing process to break the lattice that binds the antigen (i.e. OVA) to the 
Alhydrogel® and/or for the separated Alhydrogel® particles, if any, to aggregate to form 
larger and heavier particles. This explains our previous finding that subjecting the thin-film 
freeze-dried powder of aluminum salt-adjuvanted vaccines, e.g. GSK’s Engerix-BTM, to 
repeated slow freezing-and-thawing cycles does not cause particle aggregation upon 
reconstitution (159).  
In the present study, we further tested whether the immunogenicity of thin-film 
freeze-dried OVA/Alhydrogel® vaccine is affected after it was subjected to three cycles of 
repeated slow freezing-and-thawing and reconstitution. Changes (or lack of them) in the 
immunogenicity of a vaccine are difficult to predict. Any slight change in the physical and 
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chemical characteristics of the antigen (i.e. OVA) and/or the vaccine if inadvertently 
subjected to freezing can potentially lead to a decrease in the immunogenicity of the 
vaccine. Shown in Table 3 are the particle size distributions of the OVA/Alhydrogel® 
vaccine in liquid suspension or as dry powder, before and after being subjected to three 
cycles of slow freezing-and-thawing (i.e. F/T stress). As expected (159), after the 
OVA/Alhydrogel® vaccine in liquid suspension was subjected to three cycles of slow 
freezing-and-thawing, the X50 value increased by 8.6-fold (i.e. from 7.5 to ~64 µm) (Table 
3), but subjecting the thin-film freeze-dried OVA/Alhydrogel® powder to the same three 
cycles of freezing-and-thawing did not cause any significant change in the particle size and 
size distribution (Table 3). Data in Fig. 4 show that the serum anti-OVA IgG levels in mice 
immunized with OVA/Alhydrogel® dry powder that was subjected to the slow freezing-
and-thawing cycles are not significantly different from that in mice that were immunized 
with OVA/Alhydrogel® dry powder that was not subjected to the freeze-and-thaw cycles, 
or in mice that were immunized with freshly prepared OVA/Alhydrogel® liquid vaccine 
(Fig. 4). On the other hand, the serum anti-OVA IgG levels in mice that were immunized 
with OVA/Alhydrogel® liquid vaccine that was subjected to three cycles of slow freezing-
and-thawing are significantly lower than that in mice immunized with the freshly prepared 
OVA/Alhydrogel® liquid vaccine (Fig. 4). It is clear that the OVA/Alhydrogel® liquid 
vaccine is sensitive to freezing, because freezing caused significant particle aggregation 
(Table 3) and significantly reduced its immunogenicity (Fig. 4). It was reported previously 
that subjecting OVA protein to 5 repeated freezing-and-thawing cycles induces OVA 
denaturation in a concentration dependent manner (160). However, it is unclear to what 
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extent the reduction in the immunogenicity (i.e. anti-OVA IgG levels) of the 
OVA/Alhydrogel® liquid vaccine after it was subjected to repeated freezing-and-thawing 
cycles can be attributed to OVA denaturation in the present study. It is certain though that 
converting the OVA/ Alhydrogel® vaccine from liquid suspension to dry powder by thin-
film freeze-drying can protect the vaccine from damages induced by slow freezing (and 
























Figure 3.4  Effect of repeated freezing-and-thawing on the immunogenicity of the 
dry vaccine powder 
Serum anti-OVA IgG levels in mice immunized with dry powder that was subjected to 
three cycles of freezing-and-thawing (F/T) and then reconstitution or the same 
OVA/Alhydrogel® liquid vaccine subjected to the same three cycles of freezing-and-
thawing. As controls, mice were immunized with freshly prepared OVA/Alhydrogel® 
liquid vaccine or dry powder upon reconstitution. Female BALB/c mice (n = 5) were 
injected (s.c.) on days 0, 14, and 28 with 5 μg of OVA per mouse. Total anti-OVA IgG 
levels in serum samples were measured about three weeks after the third immunization. 







X10 (µm) X50 (µm) X90 (µm) 
OVA/Alhydrogel® FV  2.13 ± 0.35 7.51 ± 1.92 26.66 ± 11.35 
OVA/Alhydrogel® TFFD 2.83 ± 0.06 7.58 ± 0.21 22.27 ± 2.15 
OVA/Alhydrogel® FV, F/T 12.35 ± 0.48  64.31 ± 1.86 137.39 ± 3.31 
OVA/Alhydrogel® TFFD, F/T 1.36 ± 0.05 5.01 ± 0.29 16.15 ± 2.19 
Table 3.3  Effect of repeated freezing-and-thawing on the particle size and size 
distribution of OVA/Alhydrogel® vaccine dry powder 
The particle size distributions of freshly prepared OVA/Alhydrogel® liquid vaccine 
(i.e., OVA/Alhydrogel® FV) or thin-film freeze-dried OVA/Alhydrogel® vaccine 
powder after reconstitution (i.e., OVA/Alhydrogel® TFFD) were measured before 
or after they were subjected to 3 cycles of freeze-and-thaw (F/T). X10, X50, and X90 
denote particle dimensions corresponding to 10%, 50%, and 90% of the cumulative 












The development of aluminum salt-adjuvanted vaccines that can be managed in 
CTC or potentially in ambient temperatures and are not sensitive to freezing will not only 
help decrease the loss of global vaccine supplies due to breaches in cold-chain, but also 
avoid the unintentional administration of damaged, suboptimal vaccines to patients. Data 
in the present study confirm that TFFD is a technology that can potentially enable the 
development of such vaccines. The traditional TFFD process involves dropping droplets 
of liquid (e.g. a liquid suspension of vaccine) over a cryogenically-cooled substrate, e.g. 
the surface of a rotating cooled metal drum, to form frozen thin-film upon impact (70).  We 
also showed that the inner surface of silanized glass vials can be used as a cryogenically-
cooled substrate as well to drop liquid vaccine droplets onto to form frozen thin-films upon 
impact. Subsequently, the glass vials with the frozen vaccine thin films can be subjected to 
standard lyophilization to remove water. As shown in Fig. 5, the particle size distribution 
of OVA/Alhydrogel® reconstituted from the dry powder prepared by single vial TFFD is 
similar to that of the freshly prepared OVA/Alhydrogel® liquid vaccine or that 
reconstituted from the dry powder prepared by the traditional TFFD. As expected (60, 143-
147), slow tray-freezing followed by lyophilization led to significant aggregation of the 
OVA/Alhydrogel® vaccine (Fig. 5). The feasibility of TFFD in single vials is expected to 
allow the TFFD technology to be readily adopted in existing freeze-drying facilities with 
minimal modifications.  
It is worth mentioning that besides TFFD, other freezing and/or drying techniques 
are also explored to convert protein products into dry powders (61-64). Spray freeze-drying 
has been particularly studied to convert aluminum salt-adjuvanted vaccines into dry  
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Figure 3.5  Single vial thin-film freeze-drying 
Representative particle size distribution curves of OVA/Alhydrogel® vaccine before (i.e. 
OVA/Alhydrogel®, FV, □) and after it was subjected to thin-film freezing on a pre-cooled 
rotating metal drum (OVA/Alhydrogel®, TFFD, ○), thin-film freeze-drying on the inner 
surface of a silalized glass vial (OVA/Alhydrogel®, single vial TFFD, Δ), or conventional 
tray-freezing (OVA/Alhydrogel®, Tray freezing, ◊), and then lyophilization and 
reconstitution (FV, fresh vaccine; TFFD, thin-film freeze-drying). The experiment was 
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powder using various excipients (e.g. mixture of glycine, mannitol, and dextran up to 10% 
w/v) (67, 181). Besides the approach of converting aluminum salt-adjuvanted vaccine from 
liquid suspension to dry powder, there are also reports that certain excipients such as high 
concentrations of phosphate anions and histidine can help improve the thermal stability of 
vaccine. In addition, polyols such as propylene glycol and glycerol can help make vaccine 
insensitive to freezing (157, 164-166). Neither one of those approaches alone will likely be 
universally applicable to all vaccines, but it is certain, as demonstrated in the present study, 
that technologies are available to make aluminum salt-adjuvanted vaccines thermostable. 
3.4  CONCLUSION 
In conclusion, using a model vaccine prepared by adsorbing OVA onto 
Alhydrogel®, we confirmed that the vaccine dry powder prepared using TFFD is stable in 
temperatures as high as 40°C for 3 months and no longer sensitive to slow freezing. Global 






Novel dry powder formulation of aluminum salt-adjuvanted vaccine for 
intranasal vaccination  
4.1 INTRODUCTION 
 Adjuvants are needed for newer generation vaccines, such as protein subunit 
vaccines to elicit a strong immune response (182). Some insoluble aluminum salts, e.g. 
aluminum (oxy)hydroxide and aluminum (hydroxy)phosphate, are used in many currently 
licensed vaccines as adjuvants and possess excellent safety profiles (140, 141). A major 
limitation with aluminum salt-adjuvanted vaccines is that they must be maintained in cold-
chain (2-8 °C) during transport and storage (148). Accidentally subjecting the vaccines to 
freezing compromises their potency and/or efficacy. To overcome this issue, previously 
we reported that thin-film freeze-drying (TFFD) can be used to convert aluminum salt-
adjuvanted vaccines from liquid to dry powder without causing particle aggregation or 
decreasing the immunogenicity following reconstitution (159, 183). Importantly, the 
resultant dry powder vaccine can be stored in temperatures as high as 40 0C for an extended 
period of time (183).  
Aluminum salt-adjuvanted vaccines are generally administered by subcutaneous, 
intradermal, or intramuscular injection. However, reconstituting the dry powder vaccine 
before injection has various limitations such as the need for sterile water for injection, the 
need for trained medical personnel, and the increased chance of error made when 
reconstituting the powder and filling syringes. The nasal route for immunization offers 
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some interesting opportunities. Almost all infectious agents enter the body through the 
mucosal surfaces (80), and the nasal mucosa is often the first point of contact for inhaled 
pathogens. Therefore, ideally, to more effectively protect against inhaled pathogens, 
vaccines should be administered via the nasal mucosal surface to induce mucosal immunity 
to prevent infectious agents from entering the host (81). Besides enabling vaccines to 
induce both mucosal and systemic immune responses (82, 83), intranasal immunization 
has several other advantages as well. For example, the nose tissue is easily accessible and 
highly vascularized, and can be used in the case of epidemics for mass vaccination. In 
addition, nasal immunization enables needle-free, non-invasive delivery of vaccines with 
the possibility of self-immunization.  
 Previously, it was thought that aluminum salt-based adjuvants are not capable of 
potentiating mucosal immune responses when given intranasally, and results from prior 
studies were ambiguous (94-97). However, data from our recent studies clearly showed 
that intranasal immunization with antigens adsorbed on Alhydrogel® induces significantly 
stronger antigen-specific immune responses, both systemically and in nasal and lung 
mucosa, as compared to intranasal immunization with the antigens alone (98). In the 
present study, we tested the feasibility of administering aluminum salt-adjuvanted dry 
powder vaccine prepared using thin-film freeze-drying method directly via the nasal route 
to induce specific mucosal and systemic immune responses in a rat model. Others have 
administered dry powder vaccines intranasally in animal models (184, 185), and even in 
clinical trials (186, 187), but these vaccines do not contain aluminum salts as adjuvants. 
Aluminum salt-adjuvanted dry powder vaccine preparations have also been administered 
 91 
in animal model in a needle-free method, bur by needle-free intradermal injection (63, 
188). In our opinion, this would be the first report of successfully using aluminum salt-
























4.2 MATERIALS AND METHODS 
4.2.1 Preparation of dry powder vaccine 
The ovalbumin (OVA)-Alhydrogel® dry powder vaccine was prepared as described 
previously (159, 183). Briefly, OVA-Alhydrogel® liquid vaccine was prepared by adding 
10 mL of Alhydrogel® (10 mg/mL aluminum, manufactured by Brenntag, and supplied by 
InvivoGen, San Diego, CA) into a 50-mL tube followed by the addition of 10 mL of an 
OVA solution (1 mg/mL in 0.9% w/v saline solution), and 200 mg of trehalose (Sigma-
Aldrich, St. Louis, MO) to obtain a final formulation with 2% (w/v) of trehalose, ~1% 
(w/v) of Alhydrogel®, and 0.5 mg/mL of OVA. The vaccine suspension was converted into 
a dry powder using previously reported thin-film freeze-drying method (159, 183). The 
powder was dried using a VirTis AdVantage Bench Top Lyophilizer (The VirTis 
Company, Inc. Gardiner, NY). Lyophilization was performed over 72 h at pressures less 
than 200 mTorr, while the shelf temperature was gradually ramped up from −40 °C to 26 
°C. After lyophilization, the solid dry powder vaccine was transferred into a sealed 
container and stored in a desiccator.  
4.2.2 Physicochemical characterization 
4.2.2.1 Particle size analysis 
Geometric diameter of the dry powder vaccine was determined by low angle light 
scattering using a Malvern Spraytec® (Malvern, UK) outfitted with an inhalation cell and 
without an induction port. The nasal dry powder delivery device filled with the powder 
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was secured to the mouth of the induction port by a molded silicone adapter. The 
measurement was done at a flow rate of 25 L/min, providing a 2 kPa pressure drop across 
the device. Data acquisition took place over 4 s and only when laser transmission dropped 
below 95%.  
4.2.2.2 Powder morphology and uniformity of distribution 
Scanning electron microscopy (SEM) attached to energy-dispersive spectroscopy 
(EDS) was applied to understand the structure and morphology of the dry powder vaccine, 
and to determine the uniformity of distribution of the dry powder vaccine. Hitachi S-5500 
SEM (Hitachi High Technologies America, Inc., Pleasanton, CA) equipped with EDS was 
used at 10 kV accelerating voltage after sputter-coating the specimen with silver for 30 s 
in vacuum. Images at different magnifications are photographed from SEM, and EDS plots 
showing elemental mapping are reported. 
4.2.2.3 Flow properties 
The tapped density of the dry powder vaccine was measured according to a method 
adapted from the United States Pharmacopeia (USP) <616> method I. An adaptation was 
made due to the limited supply of powder for testing, where a 100-mL graduated cylinder 
was replaced by a 5-mL graduated cylinder. Hausner ratio and Carr’s compressibility index 
were calculated for each formulation based on USP guidelines. Measurements of the static 
angle of repose of the dry powder vaccine were conducted as per USP <1174>. 
Approximately 10 mL of powder was measured using a funnel and a flat collection surface.  
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4.2.3 Aerodynamic assessment of the dry powder vaccine 
Aerodynamic assessment of the dry powder vaccine intended for nasal 
administration was performed in a nasal cast model. The casts were made from CT scans 
of human adult noses (189) and can be divided into four sections representing the anterior 
region making up the vestibule (V) and nasal valve area; lower, middle and upper turbinates 
collectively called posterior nasal cavity (P); nasopharynx region (N); and the post-nasal 
fraction (F), which can either be collected in a cup if the model is operated without 
simulated inspiration airflow, or a removable filter is connected to the nasopharynx section 
if operated at a normal nasal breathing of 15 L/min. The cast was coated with 1% Tween 
20 in methanol and allowed to dry prior to deposition studies to mimic the mucus layer and 
minimize particle bounce (190). The formulations were administered to the cast with a 
nasal dry powder delivery device prepared in our laboratory. The spray administration 
angle was set at 60° from horizontal, and the tip of the device was inserted at a distance of 
5 mm. After administration, the cast was disassembled and all parts were washed with 2% 
nitric acid carefully to collect the deposited fractions. Aluminum content was determined 
using a Varian 710-ES Inductively Coupled Plasma-Optical Emission Spectrometer (ICP-
OES) in the Civil Architectural and Environmental Engineering Department at The 
University of Texas at Austin. The deposition profile is shown as % deposition of recovery 
in different sections of the cast model.  
 95 
4.2.4 Animal studies 
All animal studies were conducted following the U.S. National Research Council 
Guidelines for the Care and Use of Laboratory Animals. The Institutional Animal Care and 
Use Committee at The University of Texas at Austin approved the animal protocol. Female 
Sprague-Dowley rats, 6-8 weeks of age, were from Charles River Laboratories Inc. 
(Wilmington, MA). Rats were dosed intranasally on days 0, 14 and 28 with the OVA-
Alhydrogel® dry powder vaccine (IN Powder, n = 4) using our nasal dry powder delivery 
device. The rats were anesthetized and placed on their back at an angle of 45°. The exit 
diffuser of the device loaded with the vaccine powder was placed in the right nostril of the 
anesthetized rat. The plunger of the syringe that contains 1 mL of air was depressed to 
create a powder plume of the vaccine in the nasal cavity. As controls, rats were also 
intranasally dosed with the OVA-Alhydrogel® liquid vaccine (IN Liquid, n = 4), saline 
(n = 5), or subcutaneously (s.c.) injected with the OVA-Alhydrogel® liquid vaccine (SC 
Liquid, n = 4). For intranasal dosing of the liquid vaccine and normal saline, rats were 
placed on their back at an angle of 45° after anesthesia. The liquid vaccine or normal saline 
was administered using a fine pipette tip into the external nares with 10 μL volume in each 
nostril. The dose of OVA was 20 µg per rat, and 400 µg for Alhydrogel®. Four weeks after 
the third dose, rats were euthanized to collect blood, nasal wash, and bronchoalveolar 
lavage (BAL). Nasal wash and BAL were collected as previously described using 500 µL 
of sterile PBS (191).  
The anti-OVA IgG and IgA levels in serum samples, nasal washes, and BAL 
samples were determined using enzyme-linked immunosorbent assay (ELISA) (116). 
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Briefly, EIA/RIA flat bottom, NUNC Maxisorp, 96-well plates (Thermo Fisher) were 
coated with 1 ng/μL of OVA solution in carbonate buffer (0.1 M, pH 9.0) overnight at 4 
°C. Plates were blocked with horse serum for one hour before adding the blood serum. 
Horse radish peroxidase (HRP)-labeled goat anti-mouse immunoglobulin (IgG or IgA, 
5000-fold dilution, Southern Biotechnology Inc., Birmingham, AL) was added into the 
plates, and the presence of bound antibody was detected in the presence of 3,3′,5,5′-
tetramethylbenzidine solution (TMB, Sigma–Aldrich). The absorbance was read at 450 
nm.  
Brain tissues were collected from the rats upon euthanasia. The tissues were 
weighed, desiccated at 60 °C for 12 h, and then incinerated with nitric acid (6.6 N) at 60 
°C for 15 h. Aluminum content was determined using an Agilent 7500ce quadruple 
Inductively Coupled Plasma attached with Mass Spectrometer (ICP-MS) in the Department 
of Geological Sciences at The University of Texas at Austin. ICP-MS has a detection limit 
of 1 ng/L (parts per trillion) for aluminum (192). The aluminum levels are normalized to 
the dry weight of the brain tissues.  
 Noses of rats immunized by the intranasal (dry powder and liquid vaccine) and 
subcutaneous routes were prepared for histological examination. For this, the noses were 
separated, immobilized and decalcified. Afterwards the samples were sliced horizontally 
from the nostrils to the nasopharynx and slices were stained with hematoxylin and eosin 
(H&E) stain for histological evaluation. Microscopical pictures of the nasal cross section 




Statistical analyses were completed by performing two-tailed Student's t-test for 
two-group analysis or one-way ANOVA followed by Tukey’s post hoc analysis for 
multiple group comparisons (GraphPad Prism 7 software, La Jolla, CA). A p value of ≤ 
















4.3 RESULTS AND DISCUSSION 
Insoluble aluminum salt-adjuvanted vaccines contribute to more than 50% of global 
vaccines. Although search for alternative vaccine adjuvants continues today, insoluble 
aluminum salt-based adjuvants remain the preferred choice of adjuvants in vaccine 
formulations. Aluminum salt-adjuvanted vaccines, however, are particularly sensitive to 
unintentional freezing and/or heat during transport and storage, and have to be maintained 
in cold-chain (2-8 °C). Unfortunately, breaching of the cold-chain is a common place, and 
not resource limited (183). To overcome this drawback, we previously reported a method 
to convert aluminum salt-adjuvanted vaccines from liquid to dry powder without causing 
particle aggregation or decreasing the immunogenicity following reconstitution. However, 
immunization using hypodermic needles attached to syringe filled with liquid vaccine 
reconstituted from the dry powder has some inherit limitations. Data from our recent study 
showed that it is feasible to administer antigens adsorbed on an aluminum salt (i.e. 
Alhydrogel®) intranasally to induce specific systemic and mucosal immune responses (98). 
This finding led us to hypothesize that administering an aluminum-salt adjuvanted dry 
powder vaccine directly to the nose cavity will induce specific systemic and mucosal 
immune responses. We tested the hypothesis in a rat model with OVA as a model antigen 
adsorbed on Alhydrogel®, the international standard preparation of aluminum 
(oxy)hydroxide gel. OVA-Alhydrogel® liquid vaccine was converted to a dry powder using 
our previously reported thin-film freeze-drying method using 2% of trehalose as a 
cryoprotectant. The dry powder does not contain any known mucoadhesive agent. 
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4.3.1 Flow properties of the OVA-Alhydrogel® dry powder vaccine 
The flow properties measure the cohesive forces of a powder. In this study, the dry 
powder vaccine was prepared to explore the feasibility of intranasal administration, not 
their flow properties per se. However, the flow properties do affect the performance of the 
final product (193). Also, because nasal delivery requires a fluidization of the powder bed, 
it is conceivable that the flow properties of the dry powder vaccine could affect the emitted 
dose from the nasal delivery device and the deposition of the vaccine in the nasal cavity. 
The bulk and tapped densities of the dry powder was 0.040 ± 0.003 and 0.051 ± 
0.007 g/mL, respectively (Table 1). The Hausner ratio and Carr’s compressibility index of 
the dry powder vaccine was calculated to be 1.28 ± 0.07 and 21.80 ± 4.25%, respectively, 
indicating that the flow property of the powder is ‘passable’. The Angle of repose of the 
dry powder was 25.94 ± 6.30°, which indicates a good flow property. The discrepancy in 
the flow property between the two methods of measurement could be explained by the 


















Static Angle of 
Repose (º) 
0.040 ± 0.003 0.051 ± 0.007 21.80 ± 4.25 1.28 ± 0.07 
 
25.94 ± 6.30 
 
Table 4.1 Physical characterization of the TFFD dry powder vaccine 
Tapped density of TFFD dry powder was measured according to a method adapted from 
USP <616> method I using a Varian Tapped Density Tester (Varian, Palo Alto, CA). An 
adaptation was made due to the limited supply of powder for testing where 100 mL 
graduated cylinder was replaced by a 5-mL graduated cylinder. Hausner ratio and Carr’s 




4.3.2 Powder morphology and uniformity of distribution 
According to USP chapter <905>, each unit in a batch should have a drug substance 
content within narrow range of the claimed limit, which is referred to as uniformity of the 
dosage unit. The International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) Q6B also provides specifications for 
biotechnological and biological products to perform uniformity test of the dosage units of 
the biologicals. SEM/EDS has an X-ray spectrometer attached to SEM, which allows 
elemental analysis in addition to SEM. SEM/EDS could be employed to determine the 
qualitative distribution of the OVA-Alhydrogel® dry powder vaccine by taking advantage 
of the elemental aluminum in the formulation. This analysis gives an indication of how the 
vaccine is distributed in the dry powder form. Three random areas in an SEM graph (Figure 
1A, upper panel of figure 1B) were chosen for analysis, and four elements, Al, O, Na and 
Cl, were analyzed. SEM/EDS showed the presence of all four elements analyzed (Figure 
1B-C). The spectrum analysis and EDS map indicate a homogeneous distribution of the 
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Figure 4.1 (Continued) 
Shown in (A) are representative SEM images of the dry powder vaccine at different 
magnifications. (B) Randomly selected area in a SEM graph (upper panel), and 
representative elemental mapping (bottom panel). (C) EDS spectra of the elements tested 









4.3.3 Intranasal dry powder delivery device and powder characterization 
A new nasal dry powder delivery device was developed in our laboratory for this 
study. The device includes a housing reservoir and a pressurizing mechanism operable to 
pressurize gas/air chamber to desired pressure. The dry powder vaccine is loaded into the 
housing reservoir. Depressing the syringe plunger pushes air through the device, creating 
a powder plume that exits the orifice of the device (Figure 2A). The particle size of the 
OVA-Alhydrogel® dry powder vaccine was measured using a Malvern’s Spraytec 
instrument and shown in Figure 2B. The median diameter of the vaccine dry powder was 
12.55 ± 4.69 µm. According to FDA, particles greater than 10 µm are expected to deposit 




 (A)                               (B) 
 
Figure 4.2  A powder cloud evolving from the dry powder delivery device and 
particle size distribution of the dry powder vaccine 
(A) OVA-Alhyrogel® powder cloud evolving from the nasal dry powder delivery device. 
(B) A representative particle size distribution curves of the OVA-Alhydrogel® dry powder 




 4.3.4 Aerodynamic assessment of dry powder vaccine 
Nose/nasal cavity is the easiest accessible part of the respiratory system. It is worth 
noting that release of antigen from the powder vaccine to the nasal cavity must take into 
account several factors, including wettability, dissolution rate, and the interaction of 
antigen-adjuvant with the mucus. However, for a nasal vaccine to afford protection, 
vaccines must present antigen to the target lymphoid tissues in nose. Nose-associated 
lymphoid tissue (NALT) in rodents refers to a pair of aggregated lymphoid tissues in the 
bottom of nasal ducts. In human nose cavity, the Waldeyer’s ring, a well-known group of 
tonsils that includes the adenoid, tubal, palatine, and lingual tonsils, is the key lymphoid 
tissue, however (195). A post mortem study by Debertin et al. (2003) provided the first 
evidence of the existence of NALT, in addition to the Walderyer’s ring, in young children 
(196). This study in young children found disseminated aggregates of lymphoid tissues in 
38% of the cases, mainly found in the superior nasal meatus (30.1%), the middle concha 
(26.4%), the inferior nasal concha (13.5%), and the superior nasal concha (10.4%). Pabst 
stated that there is not any reported data on the frequency of NALT in adolescents and 
adults (197).  
Evaluation of nasal deposition of the dry powder vaccine would be beneficial in the 
formulation development of nasal vaccines because of the fact that there are no guidelines 
or international consensus regarding the relationship between aerosol characteristics and 
deposition sites within the nasal cavities (198). We used nasal casts obtained from the CT 
scans of five adult humans to predict the deposition of the dry powder vaccine after nasal 
administration. Figure 3A shows the representative image of the different sections of the 
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nasal casts used. The deposition study is carried out at 15 L/min. As depicted in Figure 3B, 
62.20 ± 8.14% the vaccine dry powder was recovered from the casts. Of the recovered 
powder, 64% was in the posterior nasal cavity. Overall, the nasal deposition can be deemed 
good, considering out of the total powder recovered (62.20 ± 8.14%), about 90% stayed in 




 (A)                                                         (B) 
  
Figure 4.3  Deposition of the dry powder vaccine into a nasal cast 
(A) A photo of the different sections of the nasal cast used. A - Anterior region making up 
the vestibule (V) and nasal valve area; U, M, L - upper, middle and lower turbinate regions, 
collectively called posterior nasal cavity (P); N - nasopharynx; and F - post-nasal fraction. 
(B) Deposition of the OVA-Alhydrogel® dry powder vaccine in nasal casts operated at 15 
L/min. Data are mean ± S.D. from 5 adult casts. *** p < 0.0001, posterior nasal cavity (P) 
vs. Nasopharynx (N), *** p < 0.0001, posterior nasal cavity (P) vs. Filter/post nasal (F), 












4.3.5 The immunogenicity of the dry powder vaccine after intranasal 
administration 
To evaluate the feasibility of administering the OVA-Alhydrogel® dry powder 
vaccine directly to the nose (IN Powder) to induce immune response, rats were nasally 
administered with the dry powder vaccine using our nasal dry powder delivery device. The 
immune responses induced by the same OVA-Alhydrogel® liquid vaccine after intranasal 
(IN Liquid) or subcutaneous (SC Liquid) administration were also assessed. Shown in 
Figure 4 are the OVA-specific antibody levels induced, i.e. serum IgG titers and mucosal 
IgA titers in nasal wash and BAL. Intranasal administration of the OVA-Alhydrogel® dry 
powder vaccine induced OVA-specific IgG response in rat serum samples in a level 
comparable to that induced by intranasal or subcutaneous administration of OVA-
Alhydrogel® liquid vaccine (Figure 4A). Importantly, intranasal administration of the 
OVA-Alhydrogel® dry powder vaccine also induced OVA-specific IgA in rat nasal wash 
and BAL samples, whereas subcutaneous injection of OVA-Alhydrogel® liquid vaccine 
did not (Figure 4B-C). H&E staining of mouse nasal cavities did not reveal any difference 
among rats that received the OVA-Alhydrogel® dry powder intranasally, the OVA-
Alhydrogel® liquid vaccine intranasally or subcutaneously, or normal saline intranasally 
(Figure 5), indicating that the OVA-Alhydrogel® dry powder vaccine was well tolerated 










Figure 4.4  The immunogenicity of the dry powder vaccine after intranasal 
administration  
Serum anti-OVA IgG titers and mucosal IgA titers in rats immunized with OVA-
Alhydrogel® dry powder vaccine intranasally. Rats were dosed on days 0, 14 and 28 with 
the dry powder vaccine intranasally (IN Powder, n = 4), the liquid vaccine intranasally (IN 
Liquid, n = 4), or subcutaneously with the liquid vaccine (SC Liquid, n = 4). The dose of 
OVA was 20 µg per rat, and 400 µg for Alhydrogel®. The anti-OVA IgG titers in serum 
samples (A), OVA-specific IgA titers in the nasal washes (B) and BAL samples (C) were 
measured 28 days after the third immunization. In (A), ** p = 0.001, IN Liquid vs SC 
Liquid. In (B), * p = 0.05, IN Powder vs. SC Liquid; in (C), * p = 0.01, IN Powder vs. SC 
Liquid and * p = 0.01, IN Liquid vs SC Liquid.   
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Figure 4.5  Histological examination of the nasal tissue after intranasal 
administration 
Representative histological pictures of rat nasal epithelium. Shown are H&E stained 
images of the rats intranasally dosed with OVA/Alhydrogel® dry powder vaccine (IN 
Powder) (A), s.c. dosed with OVA/Alhydrogel® liquid vaccine (SC Liquid)) (B), 
intranasally dosed with OVA/Alhydrogel® liquid vaccine (IN Liquid) (C), or intranasally 




(A) IN Powder (B) SC Liquid 
 
(C) IN Liquid (D) Saline 
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4.3.6 Aluminum biodistribution in brain 
Aluminum containing adjuvants possess excellent safety profile of close to a 
century (12, 29, 199), and it was suggested that all the injected aluminum hydroxide may 
be dissolved and absorbed eventually (200, 201). Due to the large size of the particulates 
in the OVA-Alhydrogel® vaccine dry powder and the OVA-Alhydrogel® liquid vaccine 
(i.e. X50 of ~12 µm and 8 µm, respectively), the OVA-Alhydrogel
® particles are expected 
to largely stay in the nasal cavity after nasal administration (202, 203). However, there is 
a potential of brain exposure of aluminum via the olfactory epithelium (204-206). In some 
studies, no significant brain aluminum levels were seen in rats after 4 weeks of continuous 
exposure of insoluble aluminum (oxy)hydroxide (205), while others showed elevated brain 
levels of rabbits after one month of continuous nasal exposure of soluble aluminum in 
solutions (e.g. aluminum lactate or aluminum chloride, as ‘Gelfoam’) (206).  
Therefore, we measured aluminum levels in the brain tissues of the immunized rats 
after terminal euthanasia (i.e. four weeks after the last immunization). Figure 6 shows the 
levels of aluminum determined in rat brain tissues. There was not any significant difference 
in aluminum levels among all four groups. This indicates that intranasal administration of 
the OVA-Alhydrogel® vaccine, in liquid or dry powder form, will not likely cause more 
toxicity in the brain than subcutaneous injection of the same OVA-Alhydrogel® liquid 
vaccine. For rodents, about 50% of the nasal cavity is lined with olfactory epithelium, 
compared to 3% for humans (207), which will likely further limit nose to brain transport 
in humans, if any. Therefore, it is very unlikely that transient nasal exposure of the 
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insoluble aluminum salt in vaccines for 1-3 times at a relatively low dose would result in 





Figure 4.6  Aluminum biodistribution in brain after intranasal administration 
Aluminum levels determined in rat brain tissues (µg/g of dry weight). Brain was collected 
28 days after the third immunization, desiccated, and then incinerated before determining 




As mentioned earlier, dry powder vaccines have the potential to overcome the 
stability issue of liquid vaccines (i.e. sensitive to freezing and heat). There have been a few 
reported studies investigating intranasal delivery of dry powder vaccines (184-187). 
However, to our best knowledge, the present paper represents the first study testing the 
feasibility of intranasal immunization with an aluminum salt-adjuvanted dry powder 
vaccine. Existing human nasal vaccines (e.g. FluMist) are live attenuated vaccines (208). 
Subunit vaccines provide more challenges for nasal immunization, in part due to the low 
immunogenicity of subunit protein antigens, as compared to live attenuated vaccines (209). 
Therefore, the availability of proper adjuvant(s) plays a critical role for successful nasal 
mucosal immunization. For decades, scientists have been searching for a safe and effective 
nasal mucosal vaccine adjuvant, with little success. Aluminum salts in existing injectable 
human vaccines may be repurposed as nasal mucosal vaccine adjuvants.  Furthermore, 
administering aluminum salt-adjuvanted vaccine powder intranasally can potentially 
address the cold-chain requirement associated with aluminum salt-adjuvanted liquid 





4.4  CONCLUSION 
In conclusion, in the present study we presented data demonstrating the feasibility 
of intranasally administering aluminum salt-adjuvanted dry powder vaccine to induce 
specific mucosal and systemic immune responses in a rat model. New and existing 
aluminum salt-containing vaccines may be converted into dry powder using our thin-film 
freeze-drying technology and administered without the need for needles using our nasal 
dry powder delivery device.    
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Chapter Five 
Conclusion and perspectives 
5.1       FUTURE OF INTRANASAL VACCINES: 
 The intranasal dry powder vaccines provide an opportunity to remove needles from 
traditional immunization programs, improve vaccine efficiency, and significantly impact 
healthcare in developing nations. The popularity of FluMistTM indicates that intranasal dry 
powder vaccines has long time to stay (210). Cost of immunizations is an important factor 
in accepting new methods. It is possible that intranasal dry powder vaccinations might push 
the costs of immunizations higher. The primary reason is developing these vaccine 
formulations using sophisticated technologies to manufacture in a way to maintain highest 
level of activity and then developing world-class devices to deliver the vaccines to proper 
regions in the nose. Nevertheless, all methods have limitations and each method will find 
its niche application.  
 Despite recent developments, the overall picture is one of cautious optimism, 
enthusiasm, energy, and dedication. Vaccine development is in a dynamic phase and more 
people are being reached with vaccines. There are some barriers on the way. In past decade, 
there has been significant advancement has been done to overcome the issues with vaccine 
stability and also in the field of intranasal pharmaceutics. To capitalize on the intranasal 
dry vaccine powders, it is necessary to resolve the issues surrounding the development 
process. However, recently MannKind corporation and TechnoVax Inc have combined 
their technologies to create a powder formulation of VLP Influenza vaccine for 
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intrapulmonary self-delivery by inhalation. This 'inhaled vaccine powder' for influenza is 
shelf-stable and self-inhaled (211), gives us an indication that we are not too far from 






















Aluminum salt nanoparticles induce uric acid production3 
A.1 INTRODUCTION 
Many human vaccines contain insoluble aluminum salts as adjuvants (29, 30). 
Although insoluble aluminum salts have been used in vaccines for decades, their exact 
mechanisms of action have baffled scientists for years (31, 32). Over the years, various 
theories have been proposed to explain the mechanisms underlying the adjuvant activity of 
insoluble aluminum salts. It is clear now that aluminum salts work by a mixture of different 
mechanisms. Proposed mechanisms of immunopotentiation by aluminum-containing 
adjuvants include formation of antigen depot (33, 34), stimulation of antigen-presenting 
cells such as dendritic cells (DCs) (35), complement activation (36), and stimulation of 
chemokine release (31, 36). Moreover, there are reports showing that aluminum salts 
activate intracellular pathogen pattern recognition receptor signaling pathway involving 
the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome (37, 
38). Potent inflammatory cytokines such as IL-1β and IL-18 are released in response to 
NLRP3 activation, which direct the host responses to infection and injury (39). 
Furthermore, Kool and colleagues reported that the immunopotentiating effect of 
aluminum salts depends on the induction of uric acid (40).  
                                                 
3This chapter is based on “Sachin G. Thakkar, Haiyue Xu, Xu Li, Zhengrong Cui, Journal of Drug 
Targeting” (Under review)   
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Previously we and others discovered that adjuvant activity of aluminum 
(oxy)hydroxide and aluminum (hydroxy)phosphate could be significantly improved by 
reducing the size of the particles in the aqueous suspensions of the insoluble aluminum 
salts from micrometer scale to nanometer scale (e.g. from 1-20 µm to ~100 nm) (41-44). 
We further provided evidence that the more potent adjuvant activity of the aluminum salt 
nanoparticles is likely related to their stronger ability in activating the NLRP3 
inflammasome than aluminum salt microparticles (42).  
In an effort to further elucidate the mechanisms underlying the stronger adjuvant 
activity of the aluminum salt nanoparticles, relative to microparticles, we evaluated and 
compared aluminum (oxy)hydroxide nanoparticles (AH-NPs) and microparticles (AH-
MPs) in their ability to induce uric acid production by macrophages in culture and in a 
mouse model, hypothesizing that the AH-NPs are more potent than AH-MPs in inducing 










A.2 MATERIALS AND METHODS 
A.2.1  Reagents 
Aluminum Hydroxide Nanopowder/Nanoparticles (high purity, 99.9%, # US3026) 
were from US Research Nanomaterials, Inc. (Houston TX). Polyvinylpyrrolidone, 
phosphate-buffered saline (PBS), ovalbumin (OVA), Sigma-Aldrich uric acid assay kit, 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent were from 
Sigma-Aldrich (St. Louis, MO). Cell culture medium, penicillin, streptomycin, and fetal 
bovine serum (FBS) were from Invitrogen (Carlsbad, CA). Amplex® red uric acid assay 
kit was from Molecular Probes/Life Technologies (Eugene, OR). Mouse J774A.1 
macrophage cells (# TIB-67™) were from the American Type Culture Collection 
(Manassas, VA).  
A.2.2  Preparation and characterization of aluminum (oxy)hydroxide 
nanoparticles and microparticles 
AH-NPs and AH-MPs were prepared as described previously (42). Briefly, the 
Aluminum Hydroxide Nanopowder was slowly added into warm water while stirring. The 
suspension was probe-sonicated and spun at 1000 rcf for 10 min. The supernatant was 
probe-sonicated repeatedly and spun down again at 1000 rcf for 10 min. The resultant 
supernatant in suspension was stabilized by adding polyvinylpyrrolidone (1%, w/v) and 
used as nanoparticles (AH-NPs). The sediment was re-suspended and used as 
microparticles (AH-NPs) in subsequent studies.  
 122 
The AH-NPs and AH-MPs were examined using an FEI Tecnai Transmission 
Electron Microscope (TEM) available in the Institute for Cellular and Molecular Biology 
(ICMB) Microscopy and Imaging Facility at The University of Texas at Austin. Carbon-
coated 400-mesh grids were activated for 1–2 min. One drop of the particle suspension was 
deposited on the grids and incubated for 2 min at room temperature. The grids were washed 
with water and air-dried for 1 min. Extra water was removed using filter paper and allowed 
to air-dry for 15 min before observation (41). The size of the particles was estimated based 
on randomly selected particles from the TEM micrographs. The aluminum contents in the 
AH-NPs and AH-MPs preparations were determined using a Varian 710-ES Inductively 
Coupled Plasma-Optical Emission Spectrometer (ICP-OES) in the Civil Architectural and 
Environmental Engineering Department at The University of Texas at Austin. XRD 
analysis of the AH-NPs and AH-MPs in powder was performed using an R-Axis Spider 
with a Cu sealed tube source with a large, image plate detector (Rigaku, The Woodlands, 
TX) in the Chemical Engineering Department at The University of Texas at Austin. The 
particles were lyophilized into powder before XRD analysis. All XRD patterns were 
collected with a step size of 0.01 and counting time of 1 s per step over a 2θ range of 10 to 
80.  
A.2.3  MTT assay and quantification of uric acid in cell culture medium 
Mouse J774A.1 macrophage cells were grown in DMEM supplemented with 10% 
FBS (v/v), 100 U/mL of penicillin and 100 μg/mL of streptomycin. MTT assay was used 
to determine cell viability after J774A.1 cells (2500 cells/well) were cultured with AH-NPs 
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or AH-MPs (aluminum content, 173 µg/well) for 72 h. Briefly, 20 μL of MTT reagent (5 
mg/mL) was added to the wells and incubated at 37° C in the dark for 3-4 h. Two hundred 
microliters (200 μL) of dimethyl sulfoxide was added into each well and incubated for an 
additional 15 min to solubilize the MTT-formazan product. Absorbance was measured at 
570 nm. A cell viability of greater than 90% was considered non-toxic. 
To determine uric acid production, J774A.1 cells were incubated with the AH-NPs 
or AH-MPs as mentioned above, and uric acid concentration in the cell culture medium 
was determined using a Sigma-Aldrich uric acid assay kit following the manufacturer’s 
instructions.   
A.2.4  Animal study 
The animal study was conducted following the U.S. National Research Council 
guidelines for care and use of laboratory animals. Animal protocol was approved by the 
Institutional Animal Care and Use Committee at The University of Texas at Austin. Female 
BALB/c mice (18–20 g, Charles River Laboratories, Wilmington, MA) were injected 
intraperitoneally (i.p.) with OVA-adsorbed AH-NPs (6 mice) or OVA-adsorbed AH-MPs 
(5 mice), both in a 0.9% sterile NaCl solution. The dose of aluminum was 263 µg per 
mouse, and the dose of OVA was 10 µg per mouse. As controls, mice were injected with a 
0.9% NaCl (5 mice) solution or OVA adsorbed on Alhydrogel® (aluminum, 263 µg; OVA, 
10 µg). Peritoneal lavage was collected 6 h later. Uric acid levels in the lavage samples 
were determined using the Amplex® red uric acid assay kit following the manufacturer’s 
instructions.  
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A.2.5  Statistical analysis 
Statistical analyses were completed by performing two-tailed Student's t-test for 
two-group analysis or one-way ANOVA followed by Tukey’s post hoc analysis for 
multiple group comparisons (GraphPad Prism 7 software, La Jolla, CA). A p value of ≤ 
0.05 (two-tail) was considered significant. 
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A.3 RESULTS AND DISCUSSION 
Previously, we and others showed that the adjuvant activity of aluminum salt 
nanoparticles is significantly stronger than the microparticles (41-44). It was also reported 
by Kool and colleagues that the immunopotentiating effect of ImjectTM Alum, a preparation 
that contains aluminum hydroxide and magnesium hydroxide, depends on stimulating uric 
acid release in vivo. They have found very high levels of the endogenous danger signal uric 
acid in the peritoneal lavage of mice after they were i.p. injected with OVA-adsorbed 
ImjectTM Alum (1 mg aluminim hydroxide per mouse). In addition, degradation of uric 
acid by pretreating mice with uricase abolished OVA-specific CD4+ T cell priming, 
although the effect of the uricase pretreatment on specific antibody response was not 
reported (40). Therefore, we hypothesize that the stronger adjuvant activity of aluminum 
(oxy)hydroxide nanoparticles (AH-NPs), relative to aluminum (oxy)hydroxide 
microparticles (AH-MPs), is related to difference in their ability to induce uric acid 
production, and the present study was designed to test that hypothesis.  
AH-MPs and AH-NPs were prepared from same aluminum (oxy)hydroxide 
aqueous suspension by centrifugation as described previously (42). Representative TEM 
images of the AH-NPs and AH-MPs are shown in Fig. 1A. Shown in Fig. 1B are 
representative particle size distribution curves of the AH-NPs and AH-MPs. The majority 
of the AH-NPs were below 100 nm in diameter, whereas the median diameter of the AH-
MPs (i.e., X50) was 9.43 μm, with X10 and X90 values of 1.69 μm and 17.74 μm, respectively 
(Fig. 1B). XRD analysis showed that the AH-NPs and AH-MPs have identical 





Figure A.1 Physicochemical characterization of aluminum (oxy)hydroxide 
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Figure A.1 (Continued) 
 (A) Representative TEM images of AH-NPs and AH-MPs. (B) Representative 
particle size and size distribution profiles of AH-NPs and AH-MPs as determined using 
dynamic light scattering and laser diffraction, respectively. (C) XRD patterns of the AH-

























crystallinity (Fig. 1C). Characteristic peaks of boehmite (aluminum oxyhydroxide 
(AlOOH)), based on the XRD spectra of the Joint Committee on Powder Diffraction 
Standards (PDF No. 00-021-1307), are labeled for both samples. The particles were mainly 
amorphous due to the huge characteristic peak in the 2θ range of 10-25, but they also 
contain some crystalline boehmite (Figure 1C) (44). 
To test whether the AH-NPs and AH-MPs are different in inducing uric acid 
production in cell culture, J774A.1 mouse macrophages were incubated with AH-NPs or 
AH-MPs for 72 h, and uric acid levels in cell culture medium were measured. As shown in 
Fig 2A, AH-NPs induced uric acid production, whereas AH-MPs did not. Fig. 2B shows 
the cytotoxicities of AH-NPs and AH-MPs to J774A.1 cells after 72 h of incubation at the 
same concentration as in Fig. 2A. It appears that the AH-NPs induced cell death, whereas 
the AH-MPs at the same aluminum concentration did not cause any significant cell death 
(i.e., 71% vs. 100% survival, p < 0.0001). Cell death or damage causes the release of uric 
acid, explaining why incubation of J774A.1 cells with AH-NPs caused the release of uric 
acid in cell culture medium, but incubation of same number of cells with the AH-MPs at 
the same aluminum concentration did not (Fig. 2A).  
To evaluate and compare the AH-NPs and AH-MPs on their abilities to induce uric 
acid production in vivo, AH-NPs and AH-MPs were surface-adsorbed with OVA as a 
model antigen because for immunization, aluminum salts are not injected without an 
antigen in vivo. Kool and colleagues also injected mice with ImjectTM Alum adsorbed with 
OVA in their study leading to the discovery of aluminum salt adjuvant’s ability to induce 
uric acid production in mice (40). As shown in Fig. 2C, i.p. injection of BALB/c   
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Figure A.2 (Continued) 
(A) J774A.1 cells were incubated with AH-NPs or AH-MPs for 72 h, and cell viability was 
measured. Triton-X-100 was used as a positive control (* p < 0.0001, vs. AH-MPs). (B) 
J774A.1 cells were incubated with AH-NPs or AH-MPs for 72 h, uric acid levels in culture 
medium were determined. Data shown are mean ± SEM (n = 5 – 6). *, p < 0.001 vs AH-
MPs. In A-B, the number of J774A.1 cells were 2500 cells/well, and the aluminum 
concentration was 173 µg/well. (C) Stimulation of uric acid production in BALB/c mice 
by AH-NPs and AH-MPs. Mice were i.p. injected with AH-NPs, AH-MPs, or normal 
saline, and after 6 h, uric acid levels were measured in the peritoneal lavage. AH-NPs and 
AH-MPs were adsorbed onto OVA (Aluminum, 263 µg/mouse; OVA 10 µg/mouse). Data 













mice with OVA-adsorbed AH-NPs increased uric acid level in the peritoneal lavage of 
mice, as compared to that in mice i.p. injected with normal saline. However, i.p. injection 
of OVA-adsorbed AH-MPs did not increase uric acid production as compared to i.p. 
injection of normal saline (Fig. 2C), indicating that the potent vaccine adjuvant activity of 
the AH-NPs may be due, at least in part, to their stronger ability to induce uric acid 
production. It was unexpected, however, that our AH-MPs at the concentration or dose 
tested did not cause significant uric acid release in cell culture and in the mouse model 
(Fig. 2A, C). ImjectTM Alum, which contains mainly microparticles (X10, 0.96 µm; X50, 
3.24 µm; and X90, 11.64 µm, Fig. 3A), were reported to induce significant local uric acid 
production after OVA-adsorbed ImjectTM Alum was i.p. injected into mice (40). Of course, 
the dose the ImjectTM Alum in Kool et al’s study was 1 mg per mouse (i.e. 1 mg aluminum 
hydroxide or 0.346 mg aluminum), whereas the dose of aluminum in the present study was 
0.263 mg per mouse. Moreover, the AH-MPs (i.e., X10, 1.69 μm; X50, 9.43 μm; and X90, 
17.74 μm, Fig. 1(A)) used in the present study were generally larger than the particles in 
the ImjectTM Alum (e.g. ~3-fold larger in X50). Differences in composition, particle size 
and size distribution, and dose between ImjectTM Alum and our AH-MPs may be 
responsible for their ability, or lack of ability, to induce uric acid release in vivo.  
In fact, we also tested Alhydrogel®’s ability to induce uric acid release in vivo.  
Alhydrogel® (i.e., X10, 0.67 μm; X50, 1.67 μm; and X90, 29.21 μm, Fig. 3B) at an aluminum 
dose identical to our AH-MPs, adsorbed with OVA, was also capable of inducing uric acid 
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Figure A.3 (Continued) 
(A-B) Representative particle size and size distribution profiles of Alhydrogel® (A) and ImjectTM 
Alum (B), respectively, as determined by laser diffraction. (C) Uric acid induction by Alhydrogel®. 
BALB/c mice were i.p. injected with OVA-adsorbed Alhydrogel (Aluminum, 263 µg/mouse; OVA 
10 µg/mouse) or normal saline. Uric acid levels were determined in the peritoneal lavage after 6 h. 
Data shown are mean ± SEM (n = 5). *, p < 0.0005 vs. normal saline. (D) Overlay of particle size 
distribution curves of AH-NPs, AH-MPs, ImjectTM Alum, and Alhydrogel®. The vertical dashed 
line indicates a hypothetical particle size value; aluminum salt particles smaller than that can induce 




mainly aluminum oxyhydroxide in composition, although Alhydrogel® has moderately 
high crystallinity (44), whereas our AH-MPs are mainly amorphous (Fig. 1C) (44). 
Therefore, it is very likely that the particle size and size distribution of aluminum salts 
significantly affect their ability to induce uric acid production. It is also possible that the 
smaller aluminum salt particles in Alhydrogel® and ImjectTM Alum, although not as small 
as the particles in our AH-NPs, are capable of inducing uric acid production, whereas those 
relatively larger aluminum salts, especially the very larger ones in our AH-MPs (i.e. X50 = 
9.43 µm), are not. The upper limit of the size of the aluminum salt particles that are capable 
of inducing uric acid production remains unknown, but very large aluminum salt particles 
such as the ones with a diameter ≥ 10 µm may be too large for antigen-presenting cells 
such as mouse DCs and macrophages to internalize them, preventing them from causing 
cell damage or death and inducing uric acid release. The reported average size of the rat 
alveolar macrophages is around 13 µm (212-214). We have measured the size of the 
J774A.1 mouse macrophage cells under microscope and found it to be 16.90 ± 2.47 µm (n 
= 50 cells). There are reports of macrophage uptake of particles larger than themselves, but 
the majority of the aluminum (oxy)hydroxide particles in our formulation may be too large 
for efficient uptake by mouse DCs or macrophages. Flach et al. (2011) even reported that 
mouse DC2.4 cells and human DCs differentiated from THP-1 cells did not internalize 
aluminum salt particles of ~5 µm (215). Instead, those particles induced abortive 
phagocytosis (215). Therefore, it is not unreasonable to postulate that the mechanisms by 
which smaller aluminum salt particles and larger ones potentiate immune responses are 
different (e.g. smaller vs larger than 4 µm (Fig. 3D)). Uric acid release may be related to 
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the adjuvant activity of smaller aluminum salt particles, but not that of larger particles in 
traditional aluminum salt adjuvant such as Alhydrogel®. Of course, it is possible that our 
AH-MPs at higher concentrations may cause cell damage and could in turn induce uric acid 
release as well.  
A.4  CONCLUSION  
In conclusion, the potent adjuvant activity of the aluminum (oxy)hydroxide nanoparticles 
is likely related to their ability to induce uric acid release, as compared to large aluminum 
(oxy)hydroxide microparticles. In traditional insoluble aluminum salt-based vaccine 
adjuvants, the mechanisms by which relatively smaller particles potentiate immune 
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